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SUMMARY 
 
In 2001, the National Institute for Clinical Excellence (NICE) recommended TNF-• 
inhibitors for the treatment of patients with active RA unresponsive to conventional 
DMARDs. The British Society for Rheumatology Biologics Registry (BSRBR) was 
established in October 2001 and now has 3 years follow-up, and over 7000 patients.  
 
Our study performs an analysis using a decision analytic model populated by the BSRBR 
data to evaluate the cost effectiveness of TNF inhibitors over conventional DMARD 
therapy.  In particular, we consider what is the incremental cost per QALY of TNF 
inhibitors versus traditional DMARDs according to current practice in the UK? What if 
guidance that only patients achieving moderate or good EULAR Disease Activity Score 
(DAS28) response are allowed to continue TNF inhibitor therapy after 3 months?  
Unfortunately, similar analyses based on the ACR20 or ACR50 measures are not possible 
because the BSRBR does not record the data necessary to produce these composite 
measures of relative improvement.  The analysis examines subgroups based on age, sex, 
disease duration, number of previous DMARDs, and baseline HAQ disability score.  
Sensitivity analyses consider alternative assumptions concerning interpretation of the 
evidence base, including those on HAQ disability progression on traditional DMARD, 
relationships between HAQ and utility, impact of delayed progression whilst on TNF 
inhibitors, use of sequential TNF inhibitors and discounting rates. 
 
There are several caveats and limitations detailed in the methods section of this report 
and re-iterated in the conclusions.  In particular, any mortality reduction benefits, which 
might be attributable to TNF inhibitors, are excluded. 
 
The results are analysed using a number of scenarios. The scenario on current UK 
practice gives a cost effectiveness estimate of around £24,000  per QALY. If the 
guidelines set out by NICE in their initial appraisal were strictly adhered to, and non-
responders were withdrawn from therapy, this is estimated to reduce to around £22,000.  
These numbers are within the region that NICE deemed cost effective in the previous 
appraisal e.g. ‘the incremental cost-effectiveness ratio of these therapies (etanercept and 
infliximab) can be estimated to be in the region of £27,000 to £35,000 per QALY’.   
Sensitivity analysis results show several important factors. The assessment of cost 
effectiveness in the 2001 appraisal was made using rates of discounting set at 6% cost, 
1½ QALY.  These remain in place for the 2005 appraisal but recent recommendations 
suggest moving to 3½ % cost, 3½ QALY). If the suggested new discount rates were used 
cost effectiveness would be estimated at £31,000-32,000 per QALY.  Assumptions 
concerning long-term disease progression on traditional DMARDs (i.e. the control arm) 
also make a substantial difference to cost-effectiveness.  The basecase analysis (Scott et 
al. data for the average UK progression) may be an under-estimate, and it is clear that 
treatment of patients with higher rates of progression is more cost-effective.  Under our 
assumptions, sequential therapy with 2 TNF inhibitors appears to have the same order of 
cost-effectiveness as single therapy.    
This is an independent study.  A small grant from the British Society of Rheumatologists 
has met a proportion of the costs. 
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1. INTRODUCTION 
 
1.1. BACKGROUND 
 
Rheumatoid arthritis (RA) is a chronic, progressive, inflammatory disease that affects 
approximately 0.8% of the adult population.[Symmons, 2002] RA affects the physical 
functioning of patients, their psychological and social health, and eventually progresses 
to substantial disability through the loss of mobility, increased co-morbidity and 
premature mortality.[Yelin, 1995; Pincus, 1993; Wolfe, 2003; Wong, 2001]. The 
economic burden of RA to society is substantial and approximates to that of treating 
coronary heart disease [Callahan, 1998] In 1996, the total economic impact of RA in 
England was estimated to be £1.256 billion, over half of which was accounted for by loss 
of earnings while in-patient and long-term institutional care accounted for over 50% of 
the direct medical cost [McIntosh, 1996].  
 
The addition of new disease-modifying anti-rheumatic drugs (DMARDs) such as the 
tumour necrosis factor (TNF)-a antagonists has transformed the management of RA. A 
number of clinical trials have demonstrated the efficacy of anti- TNF- a agents in 
improving function, significantly inhibiting joint destruction and reducing toxicity in 
comparison to conventional DMARDs. Costing between £8000 and £15000 per patient 
year, a recent study in the US demonstrated that the introduction of these new treatments 
increases the total annual direct cost of a biologic treated patient threefold. [Michaud, 
2004] 
 
The additional costs make these agents natural candidates for cost effectiveness analyses 
(CEA). CEA compares the incremental costs of an intervention over conventional 
management with its incremental health benefit.[Drummond, 1997] Cost utility ratios are 
the most popular CEA since health benefit is measured in quality adjusted life years 
(QALYs) allowing comparisons across other diseases on the most efficient strategy for 
resource allocation. A number of such analyses have already been developed giving a 
variety of estimates ranging from cost effective to not cost effective.[Kobelt, 2003; 
Wong, 2001; Brennan, 2004; Jobanputra, 2002; Kobelt, 2004; Bansback, 2004] Wolfe et 
al, question the validity of most estimates, since estimates of benefit have been derived 
directly from randomised controlled trials, which they argue are not representative of real 
clinical practice.[Wolfe, 2004] Kobelt et al used data from a Swedish registry, which 
does not have a control arm so does not allow a valid incremental estimate of cost utility 
to be made.[Kobelt, 2004] Therefore no existing evaluation could be considered to be 
robust.[Bansback, 2005] 
 
In 2001, the National Institute for Clinical Excellence (NICE) recommended TNF- a 
inhibitors for the treatment of patients with active RA unresponsive to conventional 
DMARDs based on their assessment of the agents encouraging cost effectiveness.[NICE, 
2002] At that time, NICE mandated that all patients with RA exposed to TNF-
a inhibitors require follow-up to assess the long-term safety and effectiveness of these 
drugs. The British Society for Rheumatology Biologics Registry (BSRBR) was 
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established in October 2001 for this purpose.[ http://www.arc.man.ac.uk 
/webbiologicsreg.htm] With up to 3 years of follow-up data, and over 7000 biologic 
treated patients recruited by the BSRBR, new questions over the cost effectiveness of 
these agents are emerging. We performed a cost-utility analysis using a decision analytic 
model populated by the BSRBR data to evaluate the cost effectiveness of TNF-a 
inhibitors over conventional DMARD therapy.  
 
1.2. RESEARCH QUESTIONS 
 
The specific research questions focussed on: 
 
1. What is the incremental cost utility (cost per QALY) of TNF inhibitors 
according to current practice in the UK versus use of traditional DMARDs 
only? 
After the patient has come off the initial TNF antagonist it is assumed that they 
would switch back to traditional DMARDs. This is the question that was initially 
reviewed by NICE, and we have focussed this work on re-evaluating whether this 
was the correct decision. 
 
2. What would be the cost utility if guidance that only patients achieving 
moderate or good EULAR Disease Activity Score (DAS28) response are 
allowed to continue TNF inhibitor therapy after 3 months?  
An important issue in the treatment of patients with TNF antagonists is the 
criterion for continuing a patient on treatment. NICE guidance follows the old 
BSR guidance which stated that patients must at least be a moderate EULAR 
responder (based on DAS28) at 3 months to continue therapy.[NICE, 2002] The 
BSRBR shows that this has not necessarily been adhered to. We have explored 
the impact of using this decision rule in the model. 
 
3. We also explore the use of a 2nd TNF antagonist in a sequence after the first 
has failed, based on a small amount of data 
 
4. What is the cost utility for subgroups based on; 
o Age 
o Sex 
o Disease duration 
o Number of previous DMARDs 
o Baseline HAQ disability score. 
 
5. What is the cost utility if we made alternative assumptions concerning 
interpretation of the evidence base, including those on 
o HAQ disability progression on traditional DMARD. 
o Relationships between HAQ and utility  
o Impact of delayed progression whilst on TNF inhibitors 
o Use of sequential TNF inhibitors 
o Discounting rates 
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1.3. FUNDING FOR THE STUDY 
 
This study was originally proposed by the authors for a research funding bid to the 
Arthritis and Rheumatism Campaign.  The bid was unsuccessful. 
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2. MATERIAL AND METHODS 
 
2.1. OVERVIEW OF APPROACH 
 
2.1.1. Modelling 
 
We developed a form of micro simulation known as an individual sampling model to 
describe the natural history of rheumatoid arthritis.  
 
We express the results in terms of quality adjusted life years (QALYs), drug related costs, 
hospitalisation costs and cost-effectiveness ratios. A stochastic analysis was performed to 
capture the parameter uncertainty. Results of this analysis are presented in the form of 
acceptability curves and net benefit distributions. 
 
The simulation tracks patients’ health from time of entry to the model until death in 6 
monthly cycles. Patients’ health is characterised in terms of their health state utility, 
which treatment they are on, and whether they remain alive. The model simulates a 
hypothetical patient that follows the course based on the experience of an average cohort. 
In contrast to a Markov approach, at each decision node a random number decides the 
route a patient takes based on calculated probability. Therefore each patient represents 
only one possible route that can be taken. The patients are replicated only 1000 times 
with different randomly sampled numbers, by which time enough routes have been taken 
to give the model precision.  
 
2.1.2. Analysis based on TNF inhibitors as a class 
 
This analysis has focussed on patients treated with etanercept (Enbrel® - Wyeth), 
infliximab (Remicade® - Schering-Plough) and adalimumab (Humira® - Abbott).  
Analyses have been performed on TNF inhibitors as a class. We have not looked at the 
differences in the cost effectiveness between TNF antagonists due to more complex 
selection bias which would not be sufficiently accounted for in the general case mix 
adjustment approach [Deeks, 2003] The BSRBR will be able to answer these questions in 
the future but further methodological work will be required. 
 
2.1.3. Data sources 
 
Overview of BSRSR data 
 
The model uses data from the British Society for Rheumatology Biologics Registry 
(BSRBR) as its primary source of evidence. 
 
This data is considered to be a valuable source for such an analysis because: 
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o This is one of the largest sources of data on the health outcomes of patients using 
TNF antagonists. 
o The data are well collected. 
o Patients are followed up, and collection is good. 
o A number of economic endpoints are collected. 
o The registry has a control arm with which to make comparisons to traditional 
DMARDs. 
 
However the challenges in using this registry are: 
 
(i) The registry is not randomised so a number of biases, in particular selection bias 
might be seen between treatment groups. For instance the availability of anti-TNF 
a was limited to patients that had failed 3 DMARDs. Therefore a number of 
patients recruited onto the control arm have yet to fail the 3 DMARDs necessary 
to attempt anti-TNF a. To control for this problem, we use case-mix adjustments 
using the treatments given as a dummy variable.  
 
(ii) The timing of measurements may not correspond to clinical events. Measurement 
of health state utility is made at baseline and then by postal questionnaire at 6 
monthly intervals. We are therefore able to derive the improvement in health 
utility for the first treatment in its first 6 months (although we do not know how it 
varies through this time). However, for subsequent treatments the postal 
questionnaire may not coincide with visits to the Rheumatologist or other events 
when treatment-switching decisions are made. Thus, we do not have a 
measurement of health utility at the time when the next treatment is attempted so 
it is difficult to access the exact magnitude of efficacy. 
 
(iii) The BSRBR is still relatively new with data on a substantial number of patients 
up only to 3 years. For making long term estimates, we need to make assumptions 
as to whether the 3 year data adequately predict long term effectiveness. Lack of 
data is particular pertinent in the control arm where recruitment has been slow and 
is limited mostly to 6 months. We therefore use external data sources for some 
parameters on the control arm. 
 
(iv) While we try to use a societal perspective, the BSRBR does not incorporate all 
components of cost and benefit necessary for a full societal approach to be made. 
Modelling can be used to synthesise such data sources from external sources, but 
after reviewing the literature reliable estimates are not reported. We have 
therefore focussed on using the data from the BSRBR. 
 
Other data sources 
Where the BSRBR was not able to provide evidence, we used sources from the literature 
that have been previously reviewed and critiqued. [Barton, 2004] 
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2.1.4. Subgroups and Covariates Analysis 
 
At the start of the model the baseline characteristics, age, sex, disease duration, number 
of previous DMARDs used, HAQ -DI, and health state utility is sampled using non 
parametric bootstrapping from the average characteristics of a sample of distinct patient 
groups. 
 
These patient groups are based on clinically meaningful characteristics: 
 
o HAQ [0-0.5, 0.5-1.0, 1.0-1.5, 1.5-2.0, 2.0-2.5, 2.5-3.0] 
o Age [<40, 40-50, 50-60, 60-70, 70+ years] 
o Disease duration [0-5,5-10,10-15,15+ years] 
o Number of previous DMARDs [<2,<3, <4, <5,5+] 
o Gender [Male, Female] 
o And whether the patient is on concomitant DMARD. 
 
These are then used as the baseline characteristics for both intervention and control 
groups. This is the appropriate methodology given the non linear nature of the analyses 
and incorporates the correlation between these variables. For example, if it is selected to 
analyse patients of higher age, then it would be more likely that the disease duration for 
this patient group would also be higher. 
 
We have used a fixed number of covariates in each of the statistical tests. We did not 
select parameters based on their statistical significance as we were not interested in why 
co variables were related to the independent variable, or which was most significant, but 
rather use all the data we had to predict most accurately. The use of holding all co 
variables in all analyses is two-fold.  Firstly, the BSRBR is an un-randomised registry so 
making comparisons between treatment groups can be confounded by selection bias. We 
selected all variables which we deemed would be important prognostic factors for the 
different outcomes and adjusted for each for these.[Deeks, 2003]  Secondly, since we 
have only ~3 years of data, we want to predict the long time effects. Using time 
dependent covariates such as disease duration, age, and number of DMARDs, allows for 
this to become a time dependent model. 
 
2.1.5. Measurement of quality of life 
 
This analysis has focussed on producing a cost utility analysis where the benefits of an 
intervention are measured using QALYs. Previous models have solely looked at the 
Health Assessment Questionnaire Disability Index (HAQ -DI), a measurement of 
disability, and mapped the results directly to utility using a simple linear 
relationship.[Fries, 1982] A criticism of this approach is that only the impact of the 
treatment on functional disability is captured, and not the psychological or pain elements 
associated with the disease. For this analysis, we have a direct measure of health utility 
since the BSRBR incorporates the SF36, a generic measure of patients’ health related 
quality of life.[Ware, 1993] The SF36 can be translated to a preference based health 
utility via the SF6D.[Brazier, 2002] The SF6D incorporates domains of physical 
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functioning, role limitation, social functioning, pain, mental health and energy and 
vitality.  The SF6D has been shown to be a responsive measure in diseases of mild to 
moderate severity, but since it is based on a measure of general health, it struggles to 
distinguish between states of severe health.[Brazier, 2004]. This so called ‘floor effect’ is 
caused because the levels of ill-health described in the SF36 do not necessarily 
discriminate between the more severe states. The result is that for increasing severity of 
HAQ disability, the SF6D will not value below 0.4. (Figure 1) 
 
 
Figure 1: Scatter plot of HAQ -DI versus SF6D using BSRBR data. 
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We have therefore attempted to provide an alternative measure of health utility, the 
EQ5D.[Brooks, 1996; Dolan, 1997] The EQ5D is a popular measure given its ease of 
application. It measures five domains, mobility, self care, usual activities, pain, anxiety. 
Since EQ5D was not measured directly in the registry, we used a mapping of the HAQ 
disability questionnaire to the EQ5D.[Bansback, in submission] This mapping imputes 
the EQ5D from all the 42 components of the HAQ questionnaire so is more sophisticated 
than the simple linear relationships previously used. Since this is not a direct 
measurement of EQ5D, it is inferior to the SF6D in terms of its accuracy of 
measurement. However, it has been shown that the EQ5D is better at distinguishing 
between states of severe health in RA [Marra, 2004]  
 
Figure 2shows that it captures a greater range of values, particularly in severe states while 
Figure 3 shows how the two measures relate. 
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Figure 2: Scatter plot of HAQ -DI versus imputed EQ5D 
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Figure 3: Scatter plot of SF6D versus imputed EQ5D 
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2.1.6. Probabilistic Sensitivity Analysis Approach 
 
The uncertainty in model parameters is characterised using probability distributions. 
Where possible we characterised joint probability distributions for all the uncertain 
parameters. This was accomplished by using multivariate normal distributions to describe 
the correlation in uncertainty between the results of the statistical analyses. To do this, the 
variance covariance matrix is used to capture the joint distributions. Where joint 
distributions are not described we assume independence between the uncertainty in 
parameters.   
 
Monte Carlo sampling is used to propagate the parameter uncertainty in the cost 
effectiveness model. This entails making random draws of the uncertain parameters from 
their (joint) probability distribution, running the model for each simulated set of 
parameters and collecting the outputs from each run.[Briggs, 2001] These are then a 
random sample from the induced probability distribution of model outputs. This process 
is known as ‘probabilistic sensitivity analysis’ (PSA).  Outputs from the model include 
mean costs and mean effectiveness. In comparing the cost-effectiveness of two strategies, 
uncertainty about incremental mean costs and effectiveness can be displayed in the 
incremental cost-effectiveness plane as a scatter plot of the Monte Carlo output samples. 
When choosing between two strategies, decision uncertainty is usually expressed 
graphically through the cost-effectiveness acceptability curve (CEAC), which plots the 
probability that one treatment is more cost-effective than the other as a function of the 
societal willingness to pay threshold value of a QALY. 
 
Decisions about whether to reimburse interventions are made with decision uncertainty. 
The consequences of decision uncertainty, in terms of wasted resources and health gain 
forgone, can be calculated to inform whether additional evidence should be collected in 
order that the decision can be reviewed in the future. This is the basis of value of 
information analysis which can identify those areas where reducing the uncertainty would 
have the greatest impact upon the decision uncertainty. We present the results of the 
global expected value of information. 
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2.2. MODEL PATHWAYS DESCRIPTION 
 
The model pathway is described in Figure 4. 
 
For each modelled patient we examine  
 
o Initial DAS28 response (either a moderate, good, or non DAS28 responder based 
on their current age, disease duration, number of previous DMARDs, level of 
health state utility, gender) 
o Improvement in health utility over the first 6 months (based on a number of 
demographic and clinical characteristics, along with the type of treatment they are 
on, and the type of DAS28 response they are predicted to achieve.) 
o Utility progression 6 months onward 
o The length of time a patient remains on each treatment  (dependent variables such 
as age, disease duration, number of previous DMARDs and the type of DAS 
response they are predicted to achieve) 
 
Alongside this we examine  
 
o Drug and monitoring costs 
o Costs associated with hospitalisation 
 
When the patient reaches his/her time to withdraw, the model moves on to a 2nd treatment 
in the sequence, then a 3rd etc…up to 6 treatments.  As all the estimates include time 
dependent variables such as age, disease duration and number of previous DMARDs, at 
each point the patient withdraws from a treatment and switches to the next, the 
probabilities of response, magnitude of improvement and time to withdrawal will be 
different.  We do not specify particular DMARDs at different positions in the sequence 
but rather use the same generalised DMARD in each position based on a weighted 
average of BSRBR patients DMARD use.  After the 6th treatment we assume patients will 
no longer respond but will still receive some maintenance therapy on DMARDs. 
 
The model runs the same patient through 2 arms i.e. TNF inhibitor therapy versus 
traditional DMARDs. 
 
The formulation of each of these analyses is given in the next section. 
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Figure 4: Example of how analyses link together over time to predict health state utility, time on treatment and cost.
TREATMENT 1 TREATMENT 2  
DAS response type ~ 
 Aget 
 Disease durationt 
 Number DMARDsn 
 Gender 
 Treatment1 
Time to withdrawal ~ 
 DAS responset 
 Aget 
 Disease durationt 
 Number DMARDsn 
 Gender 
 Concomitant DMARD 
 Treatment1 
Improvement in utility ~ 
 Utilityt 
 DAS responset 
 Aget 
 Disease durationt 
 Number DMARDsn 
 Gender 
 Treatment1 
Utility progression 
Disease duration / age  
(t)        (t+1)        (t+2)  (t+x) 
Number of DMARDs  
Drug Costs & monitoring  
and administration ~ 
 Treatment1 
Hospitalisation Cost ~ 
 Utilityt - t+1 
 Aget - t+1 
 Disease durationt - t+1 
 Number DMARDsn 
 Gender 
 Treatment1 
  
DAS response type ~ 
 Aget+1 
 Disease durationt+1 
 Number DMARDsn+1 
 Gender 
 Treatment2 
Time to withdrawal ~ 
 DAS responset+1 
 Aget+1 
 Disease durationt+1 
 Number DMARDsn+1 
 Gender 
 Concomitant DMARD 
 Treatment2 
Improvement in utility ~ 
 Utilityt+1 
 DAS responset+1 
 Aget+1 
 Disease durationt+1 
 Number DMARDsn+1 
 Gender 
 Treatment2 
Utility progression 
Drug Costs & monitoring  
and administration ~ 
 Treatment2 
Hospitalisation Cost ~ 
 Utilityt+1 - t+2 
 Aget+1 - t+2 
 Disease durationt+1 - t+2 
 Number DMARDsn+1 
 Gender 
 Treatment2 
  
 
Repeat  until death 
(n) (n+1) (n+2) 
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2.3. PROBABILITY OF RESPONSE TO TNF INHIBITOR AND TRADITIONAL 
DMARD THERAPY 
 
We estimate the probability of DAS28 (EULAR) response (non/ moderate/ good) using a 
proportional odds cumulative Logit model (Table 1)  
 
The probability of DAS28 response type is sampled at each point when a new treatment 
is attempted. Therefore, the probability is dependent on how long the patient has been on 
their existing treatments and the number of exisiting treatments.  
 
Table 1 Statistical modelling of proportional odds cumulative Logit model for predicting type of 
response 
 
Table 2: Results of proportional odds cumulative Logit model for predicting type of response 
Co variable  SF6D EQ5D 
x1 Health state utility 2.2691 1.0275 
x2 Age (years) -0.0209 -0.0182 
x3 Disease duration (years) 0.0097 0.0098 
x4 Previous number of DMARDs -0.0676 -0.0624 
x5 Gender (0=Male, 1=Female) -0.3162 -0.2932 
x6 Whether on TNF inhibitor (1=Yes) 0.5608 0.6318 
1a  None | Moderate or Good intercept -1.1451 -1.6849 
2a  None or Moderate | Good intercept 1.3917 0.8650 
 
 
Let 1p  2p and 3p be the probability of a DAS response 0 (poor), 1 (moderate) or 2 
(good) 
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We fit the model 
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To predict the probability of a DAS response we use the equations 
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where the γ are the coefficients for the covariates. 
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A positive coefficient signals an increasing chance of successful response. Thus patients 
that are older, have had more previous DMARDs or are female, are less likely to have 
successful response, whilst those who have higher baseline utility, or are on a TNFα  
inhibitor are more likely to respond. 
 
The coefficient for disease duration is counter intuitive since patients with a greater 
disease duration appear to be more likely to respond. For an individual tracked through 
our model, this is counter balanced by the age coefficient. 
 
The variance-covariance matrix for these regression parameters, were recorded and have 
been used in probabilistic sensitivity analysis initialising a multi-variable normal 
distribution.  
 
Figure 5shows an example of how age and disease duration and treatment are estimated 
to affect the probability of type of response for a patient in the intervention and control 
arms over 10 years in the model. The exact probabilities change dependent on the type of 
patient. 
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Figure 5: Example of probability of DAS response type over time for an average patient on the 
intervention arm (top) and control arm (bottom) 
 
 
Graphs shown are for an average patient in the BSRBR (female, aged 55, baseline SF6D 
0.53, baseline HAQ equal to 2.1, disease duration of 14 years, attempted 5 previous 
DMARDs)  
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2.4. INITIAL IMPROVEMENT ON TNF INHIBITOR AND TRADITIONAL 
DMARD THERAPY 
 
Table 3 Statistical Modelling of Initial Improvement on TNF inhibitor and Traditional DMARD 
Therapy 
 
The magnitude of improvement (can be worsening) in the first 6 months of a new 
treatment is then estimated using a multivariate regression model. This used demographic 
and clinical variables along with the type of DAS28 response. (Table 4) 
 
Predict utility at six month (x+1) from baseline x 
 
We assume utility at 6 months is normally distributed with mean µ 
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Where β is the coefficient for the baseline utility uo and the γ are the coefficient for the other 
covariates. 
 
To predict six month utility from baseline use the formula 
( )xullutility Tgba ++= - )( 01  
 
Utility is transformed to the logit scale and vice versa to maintain utility in a reasonable range 
by: 
 
Function to transform the range –0.6 :1 to 0.025:0.975 
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)6.0(95.0)( ++= xxt  
 
Function to transform the range 0.025:0.975 to –0.6 :1  
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Table 4: Results of multivariate regression model to predict improvement in utility over 1st 6 months 
of treatment 
Co variable Description SF6D EQ5D 
0u  Health state utility at time x † 0.4972 0.3854 
x1 Age (years) -0.0026 -0.0049 
x2 Disease duration (years) -0.0002 -0.0046 
x3 Previous number of DMARDs -0.0132 -0.0176 
x4 Gender (1=Male?) 0.0256 -0.0419 
x5 Whether on TNF inhibitor (1=Yes) 0.0967 0.1753 
x6 No DAS28 response reference reference 
x7 Moderate DAS28 response 0.1482 0.2387 
x8 Good DAS28 response 0.2936 0.4922 
a  Intercept 0.5453 0.5629 
 
The results show that patients who are older, have greater disease duration, or higher 
previous DMARD use achieve slightly lower utility improvements. Patients who receive 
a TNF inhibitor, or are DAS28 moderate or good responders achieve higher utility 
improvements.  Note, that in each case, the EQ5D utility coefficients are approximately 
twice the size of those for SF6D 
 
The variance-covariance matrix for these regression parameters, were recorded and have 
been used in probabilistic sensitivity analysis initialising a multi-variable normal 
distribution.  
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Figure 6: Magnitude of utility improvement in the first 6 months based on type of DAS response for 
average patient on intervention arm (top) and control arm (bottom) 
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Graphs shown are for an average patient in the BSRBR (female, aged 55, baseline SF6D 
0.53 (EQ5D=0.31), baseline HAQ equal to 2.1, disease duration of 14 years, attempted 5 
previous DMARDs) 
 
It is apparent from trial evidence on biologics that improvements in disability occur 
quickly in responders to TNFα treatment. Instead of assuming a straight line between 0 
and 6 months, we have adjusted the utility improvement to reflect this. We assume that 
80% of a patient’s total response will be achieved within the first month. (see figure 7) 
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Figure 7: Illustration of assumption over utility improvement 
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2.5. DURATION OF TNF INHIBITOR TREATMENT – TIME TO 
WITHDRAWAL 
 
The time on TNF inhibitor treatment is modelled using a Weibull survival analysis. For 
this analysis, we assumed that patients could only switch treatment at each 6 monthly 
interval. In the registry, it was apparent that switching sometimes occurred between these 
clinical assessments. We however made the assumption that the therapy that the patient 
ended the period on, was the predominant therapy for the entire period.  
 
The type of response a patient is predicted to have achieved is used in estimating the 
duration on treatment in two ways. First, the type of DAS28 response the patient has 
achieved is used to predict the time the patient will spend on therapy. We found that 
patients who achieved a good DAS28 response, would remain on TNF antagonist 
treatment for longer than moderate or non responders. (Results of a multivariate Weibull 
survival analysis on treatment are found inTable 6). Secondly, dependent on the rule for 
deciding whether a patient should remain on therapy, the type of DAS28 response is used 
to remove patients after 3 months or 6 months.  For instance, the current NICE guidelines 
specify that patients should be at least a moderate responder at 3 months to remain on 
treatment.[NICE, 2004] If that rule is selected, and the patient is sampled to be a non 
responder, the Weibull regression will estimate the time on treatment and if this is 3 
months, the decision rule is used and withdraws them at this point.  
 
Table 5 Statistical Modelling of Weibull survival analysis 
 
 
The baseline hazard function is  
1
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a tth  
Where a is the shape and b the scale parameter and t is the time in months A 
proportional hazards model is fitted for adjusting the survival for covariates.  
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The model is fitted twice. Firstly where the survival time is the time on the first TNF, 
and secondly where they are the time on any continuous TNF. 
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Table 6: Multivariate Weibull survival analysis to predict time on 1st and all TNF antagonist 
treatments 
Co variable Description First TNF All TNFs 
  SF6D EQ5D SF6D EQ5D 
x1 Age (years) -0.003 -0.003 0.0162 0.0154 
x2 Disease duration (years) 0.001 0.002 0.0079 0.0061 
x3 Previous number of DMARDs 0.066 0.066 0.0587 0.0675 
x4 Gender (1=Male?) -0.750 -0.454 -1.0462 -0.8764 
x5 Whether on TNF inhibitor 
(1=Yes) 
0.137 0.175 0.0918 0.1083 
x6 On concomitant DMARD 0.042 0.078 -0.1630 -0.1166 
 No DAS response reference  reference  
x7 Moderate DAS response -1.264 -1.232 -1.2307 -1.2783 
x8 Good DAS response -1.882 -1.777 -1.7873 -1.6193 
log( b ) log(scale) 3.764 3.772 4.1826 4.1883 
log(a ) log(shape) 0.588 0.582 0.7979 0.8085 
 
 
The variance-covariance matrix for these regression parameters, were recorded and have 
been used in probabilistic sensitivity analysis initialising a multi-variable normal 
distribution.  
 
The existing guidelines on prescribing anti TNF-αs, mandated by NICE recommended 
that patients should only continue therapy if they were at least a moderate responder in 
the first 3 months of treatment. More recent guidelines from the BSR state that 6 months 
is a more appropriate guideline. Since the BSRBR only collects data at 6 monthly 
intervals, it was difficult to assess the impact of this issue on the cost utility of anti 
TNFαs directly from the data.   
 
Sometimes, patients who are DAS28 non responders are sampled with a worsening 
utility. It might be argued that if a patient is showing a disutility due to a treatment it 
would be stopped. We have looked at this option only in the sensitivity analysis since 
quality of life is not explicitly used as a decision rule by clinician or patient, particularly 
if it is a small change which would not necessarily be detectable by a patient (<0.1). This 
decision rule applies both to TNF inhibitor and traditional DMARD therapy 
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2.6. DURATION OF DMARD TREATMENT – TIME TO WITHDRAWAL 
 
For estimating the time to withdrawal on a DMARD, since most of the BSRBR data were 
limited to just the first 6 months, we could not use a survival analysis to estimate long 
term survival on DMARD treatment. Instead we used figures from Weibull distributions 
averaged over all DMARDs from the literature. [Barton et al.] 
 
However, unlike the TNF antagonist survival estimates, this is not dependent on the type 
of DAS28response. Therefore a patient who is sampled to be a DAS28 non responder has 
the identical survival probability on DMARDs as a DAS28 good responder.  
 
Table 7: Values for Weibull survival on DMARDs [Barton et al.] 
Co variable Description Coefficient SE 
α Scale 2.68 0.59 
β Shape 0.80 0.07 
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2.7. LONGER TERM PROGRESSION OF UTILITY WHILST ON TNF 
INHIBITOR THERAPY 
2.7.1. Assumption of Steady State Based On other Registries 
 
Registries in Sweden and also the US have published data on HAQ trends for 4 years plus 
suggesting that response to therapy is maintained.[Kobelt 2004]  In our basecase analysis 
we have assumed that utility achieved at 6 months is maintained until treatment 
withdrawal i.e. that utility progression is zero. 
 
2.7.2. Results from BSRBR data by DAS28 Response 
 
The BSRBR data have the opportunity to examine this but there are few patients with 
over 18 months follow-up. 
 
We constructed a statistical model to examine the rate of utility progression according to 
DAS28 response status at 6 months. 
 
The model is based on a similar logistic approach as in Table 3 but with covariates only 
according to DAS28 response. 
 
Table 8: Results of multivariate regression model to predict improvement in utility over 6 to 18 
months TNF inhibitor treatment. (coefficients are monthly change on the Logit scale) 
Co variable Description SF6D EQ5D 
x8 Good DAS28 response (reference) -0.001813 -0.0051 
x6 No DAS28 response (add to reference) 0.008874 0.008164 
x7 Moderate DA28S response  (add to 
reference) 0.001669 0.000909 
 
The results show that there is a slight worsening of utility for patients who achieved good 
response, whilst moderate responders have progression close to zero and poor responders 
experience some ongoing but marginal improvement in utility. 
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2.7.3. Sensitivity Analysis on delayed underlying progression using Age and 
Disease Duration Parameters. 
 
There is evidence from the trends in radiological data for TNF antagonists that patients 
on average show at least no radiological progression (some trials show improvements) 
whereas treatment with MTX and other DMARDs, even when patient respond is 
associated with radiological progression. Radiological progression has been shown to be 
strongly linked with worsening disability over the long term.[Scott, 2000].  
 
We therefore assume that patients have the same radiological damage at the end of anti-
TNFα treatment as at the start, so their ability to improve is the same at the end as the 
start. To do this, since radiological damage is not a parameter in our model, we hold 
patients age and disease duration whilst they remain on the anti-TNFα, so when they do 
discontinue, they would follow the precise path in progression they would have done had 
they gone directly to DMARDs at the time they started their TNF antagonist.  This 
concept is well explained in Kirwan et al. [Kirwan, 1999] These assumptions are 
explored in sensitivity analyses. 
 
Figure 8: Example from Kirwan on delayed progression 
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2.8. WORSENING AFTER WITHDRAWAL FROM TNF INHIBITOR 
THERAPY 
 
There are very few data on utility changes after withdrawal from TNF inhibitor. 
 
The analysis undertaken of BSRBR data suggest an overall monthly worsening on the 
logistic scale of  -0.0056.  This is a much smaller level of worsening than the initial 
improvements seen and it would be nonsensical to then apply utility improvements based 
on Table 3 from this new base because patients would be on a much higher utility than 
they achieved during their successful response to TNF inhibitor therapy. 
 
Instead we make 2 assumptions. 
 
The first assumption is that when a patient switches treatment, they worsen temporarily 
until the new treatment becomes effective. This is not seen in the long term data from the 
registry as the time point of switching treatment is different to the time when the patient 
answers the questionnaire regarding their disability and quality of life. 
 
The second assumption is the level of utility the patient will return to when they 
discontinue the treatment they are on. We made the assumption that the level they would 
reach would be dependent on the progression seen during the previous treatment, and that 
the worsening would be equal to the initial improvement (Figure 9). This is based on 
results seen when patients on etanercept were discontinued and their disability quickly 
rebounded back to near baseline.[Brennan 2004]  
 
Figure 9: Example of how utility changes at end of treatment 
 
 
 
 
 
 
 
 
 
 
 
 time 
utility 
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2.9. LONG-TERM PROGRESSION ON TRADITIONAL DMARD THERAPY 
2.9.1. HAQ DI score progression on DMARDs - Scott et Al Evidence Re-
examined 
 
We again have insufficient data to estimate the progression of utility for a patient whilst 
on DMARD therapy so we have gone to external sources. Reviewing the literature 
showed that no studies had looked at health utility progression directly. We therefore 
used HAQ DI as a proxy for utility as has been done before in economic evaluations of 
RA therapies. In a paper by Scott et al, the annual progression in HAQ -DI is assessed 
from 12 cross sectional studies.[Scott, 2000] The weighted average of annual HAQ 
progression, was calculated to be 0.042 (Table 9).  
 
Table 9: Review of DMARD progression rates from Scott et al 
 
Study Year N in study Mean annual  HAQ 
progression 
Wolfe et al 1991 561 0.020 
Lassere et al 1995 353 0.045 
Sherrer et al 1986 691 0.072 
Greenwood et al 1999 701 0.032 
Ward et al 1993 282 0.014 
Gardiner et al 1993 175 0.030 
Callahan et al 1997 100 -0.006 
Leymarie et al 1997 370 0.000 
Ward et al 1998 182 0.017 
Munro et al 1998 440 0.119 
Truro cases 1998 33 0.006 
Shipps Cross cases 1998 46 0.023 
    
Crude average   0.031 
    
Weighted average       0.042  
From Scott et al. The links between joint damage and disability in rheumatoid arthritis 
 
To estimate the uncertainty in the average progression on utility we use the figure of 0.58 
for the individual variation for a patient with established RA over 4 to 5 years in Scott et 
al. To calculate the standard error, we first make this an annual variation (0.145) and then 
divide by the square root of n-1 (=0.0023, where n=3934). This again is converted to 
utility. 
 
2.9.2. Translating HAQ DI score to Utility 
To convert this to health state utility we use results of simple linear regressions (∆SF6D = 
-0.1008 ∆HAQ , ∆EQ5D -0.2102 ∆HAQ ). [Bansback Appendix 3] 
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2.10. DRUG AND MONITORING COSTS  
 
The BSRBR gave the breakdown of treatment type for each arm. In patients taking TNF 
antagonists, up to 80% of patients were taking a concomitant DMARD. DMARDs were 
often taken in combinations of up to 4 treatments. We assumed this breakdown would 
remain constant over time as patients switch from treatment to treatment.  
 
Table 10  Percentage of patients on each DMARD and TNF inhibitor 
  TNF inhibitor 
Breakdown 
DMARD 
Breakdown 
Azathioprine 4% 1%
Hydroxychloroquine 10% 11%
Gold 2% 7%
Leflunomide 11% 16%
Methotrexate 80% 54%
Sulfasalazine 18% 38%
Ciclosporin 3% 1%
Etanercept 43% 0%
Infliximab 2nd year 44% 0%
Adalimumab 13% 0%
 
We multiplied these proportions by calculated costs for each individual treatment to gain 
a weighted cost for each strategy (divided into TNF antagonist plus concomitant 
DMARD, TNF antagonist alone, DMARD). 
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Table 11 Cost Assumptions 
 
[Note most Unit costs from BNF February 2005, Infliximab price has changed from that stated by BNF at that time and has reduced from 
£451.20 per vial to £419.62.  Earlier draft versions of this report used the higher price, the results in this final version use the new lower 
price of £419.62 per vial.] 
No treatments Dose (mg) Cost per 
Treatment Dose/ schedule 1st 6 
mths 
Sub 6 
mths 
Dose each 
treatment 
(mg) 
1st 6 
months 
sub 6 
months 
Vial 
size 
(mg) 
Cost 
per 
vial 
1st 6 
months 
Sub 6 
months 
Total 
annual 
cost 
Azathioprine 1-3mg per kg daily 182 182 150 27300 27300 2800 10 97 97 194 
Hydroxychloroquine 400mg daily 182 182 400 72800 72800 12000 5 28 28 55 
Gold 50mg (first dose 10) weekly 26 26 50 1300 1300 50 9 243 243 487 
Leflunomide 100mg for three days then 20 daily 182 182 20 3640 3640 20 2 282 282 564 
Methotrexate 15mg weekly 26 26 15.0 390 390 70 3 18 18 36 
Sulfasalazine 500mg to 2500mg once daily with dose 
increasing by 500mg each week to max 
of 3g 
840 910 500 420000 455000 56000 8 63 68 132 
Ciclosporin 3.25mg/kg daily 182 182 225 40950 40950 6750 173 1051 1051 2101 
Etanercept 25mg twice weekly 52 52 25 1300 1300 25 89 4648 4648 9296 
Infliximab 1st year  3mg/kg weeks 0, 2, 6 then every 8 5.5 3.25 210 1155 682.5 100 419.
62 
4847 2864 7711 
Infliximab 2nd Year 3mg/kg every 8 weeks 3.25 3.25 210 682.5 682.5 100 419.
62 
2864 2864 5728 
Adalimumab 40mg every other week 13 13 40 520 520 40 358 4648 4648 9295 
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Table 12  Monitoring Assumptions 
Treatment 
Outpatient 
department 
visit 
GP visit 
Half day 
Hospital 
attendance 
Full blood 
count 
Erythrocyte 
Sedimentation 
Rate/ or CRP 
Liver 
function test Chest x-ray 
Urea, 
electolytes 
and 
creatinine 
Protein and 
glucose 
Blood 
pressure Total cost 
1st 6 Months 
Azathioprine 1 12  13 1 13  1   545 
hydroxychloroquine 1 2  3 3 3     207 
Gold 1 23  24 1 24  24 24  1,078 
Leflunomide 1 12  13 1 7  1 1 13 508 
Methotrexate 1 12  13 1 13 1 13   639 
Sulfasalazine 1 7  8 1 5     343 
Ciclosporin 1 8  7 1 7  9 1 9 418 
Etanercept 1 5  6 6 6 1 6   404 
Infliximab   5 5 5 5 1 4   1142 
Adalimumab 1 5  6 6 6 1 6   404 
subsequent 6 months 
Azathioprine 1 5  6  6     280 
hydroxychloroquine 1 1  2 2 2     161 
Gold 1 8  9  9  9 9  442 
Leflunomide 1 3  4  4     209 
Methotrexate 1 5  6  6  6   317 
Sulfasalazine 1 1  2  2     139 
Ciclosporin 1 5    6     213 
Etanercept 1 2  3 3 3  3   226 
Infliximab   4 4 4 4  4   903 
Adalimumab 1 2  3 3 3  3   226 
[Unit costs from Barton et al] 
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2.10.1. Dose Assumptions 
 
The costs for each drug were calculated using the recommended dosages.[BSR 
guidelines] 
 
The amount of infliximab given to a patient is determined by their weight. The 
recommended initial dose is 3mg per kg. This is given at week 0, 2, 6 and then 
subsequent 8 weeks. We assumed 3 initial treatments in the first 6 weeks plus a 
subsequent eight weekly regimen giving an average use of 20 weeks divided by 8 i.e. 2.5 
over the remainder of the first 6 months.  The total number of treatments assumed over 
the first 6 months is therefore 5.5.  In the 2nd 6 months and beyond we assumed infusions 
eight weekly, giving an average of 26/8= 3.25 infusions per 6 month period.  Given an 
person for example of weight 70kg, this would calculate to 1155mg in the first 6 months 
and 682.5mg in subsequent 6 months.  
 
The actual dose of infliximab is recorded in the registry and showed some differences 
from this recommended dosing. The possible reasons for differences relate to the 
provision of infliximab in 100mg vials.  The dose calculated based on patient’s weight 
might leave some of a vial unused. What happens to this unused drug is not recorded in 
the registry.  It might be used on another patient,  it might be thrown away, or the patient 
might receive slightly more than the exact calculated dose.  
 
We have used the recommended licensed doses in the model’s central estimate and used 
the BSR data on reported dose in a sensitivity analysis.  
 
[Note: Earlier draft versions of the report and model used a slightly higher number of 
doses of infliximab in the first 6 months – wrongly assuming 6.25 infusions over the first 
6 month period.  This has been corrected] 
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2.10.2. Cost Summary 
 
Table 13: Summary of Drug Costs and monitoring costs at licensed dosages by treatment 
 Drug Cost 
1st 6 months 
Drug Cost 
subsequent 
6 months 
Monitoring 
1st 6 months 
Monitoring 
subsequent 
6 months 
Breakdown 
of use in 
intervention 
arm 
Breakdown 
of use in 
control arm 
Azathioprine 97 97 545 280 4% 1% 
Hydroxychloroquine 28 28 207 161 10% 11% 
Gold 243 243 1078 442 2% 7% 
Leflunomide 282 282 508 209 11% 16% 
Methotrexate 18 18 639 317 80% 54% 
Sulfasalazine 63 68 343 139 18% 38% 
Ciclosporin 1051 1051 418 213 3% 1% 
Etanercept 4648 4648 404 226 43% 0% 
Infliximab 4847 2864 1142 903 44% 0% 
Adalimumab 4648 4648 404 226 13% 0% 
 
Table 14: Summary of Total costs by treatment by 6 monthly periods 
 
 Licensed dosages Using reported dosages with dose escalation 
Monthly 
period 
Anti-TNF in 
combination with 
DMARD 
Anti-
TNF 
alone 
DMARD Anti-TNF in 
combination with 
DMARD 
Anti-
TNF 
alone 
DMARD 
0-6 £6,262 £5,464 £781 £7,265 £6,467 £781 
6-12 £4,826 £4,387 £430 £5,955 £5,516 £430 
12-18 £4,826 £4,387 £430 £6,211 £5,771 £430 
18-24 £4,826 £4,387 £430 £6,641 £6,202 £430 
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2.11. COSTS DUE TO HOSPITALISATION 
 
A regression model is used to predict the number of days per 6 months a patient is an 
inpatient. 
 
We looked at the impact of treatment on adverse events and hospitalisation by building a 
multivariate regression model looking at the number of days a patient was hospitalised 
dependent on clinical and demographic factors, along with the treatment type and health 
state utility value.(Table 15) Previous studies have shown a strong relationship between 
direct costs (predominantly drug and hospitalisations for joint replacements) and 
disability.[Michaud 2004]  
 
Table 15:  Results of multivariate regression of number of days LOS 
 
Co variable Description SF6D EQ5D 
x1 Health state utility -1.4690 -0.5467 
x2 Age (years) 0.0080 0.0078 
x3 Disease duration (years) 0.0083 0.0075 
x4 Previous number of DMARDs 0.0690 0.0648 
x5 Gender (1=Male?) -0.0611 -0.0620 
x6 Whether on TNF inhibitor (1=Yes) -0.4113 -0.3719 
x7 (Intercept) 0.7883 0.2351 
 
This was multiplied by an average cost for a day in a rheumatology unit (= £287 (range 
£145 – 368)).[Netten and Curtis, 2002](inflated to 2004).  
 
This methodology underestimates the total non drug related costs of the disease. For 
instance, it does not look separately at the breakdown of type of adverse event, or type of 
procedure that may vary between arms. This subject requires further detailed analysis, 
which the BSRBR provides good quality data to provide.  
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2.12. OTHER COSTS 
 
A number of important costs are excluded 
 
- costs of institutionalisation due to disability are excluded 
 
- costs of longer-term surgeries unless they are represented in the first 18 months of 
BSRBR data 
 
- costs to (or quality of life impact on) carers 
 
- lost work productivity due to disability among patients of working age. 
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2.13. LIFE-TABLES AND MORTALITY ASSUMPTIONS 
Life years, the other component of QALYs have not been analysed separately between 
groups. Instead we have used standard UK life tables (Table 16).[www.gad.gov.uk] We 
adjust these by standardised mortality ratios for patients with RA (Table 17).[WHO 
Global Burden of Disease programme] 
 
Whilst evidence is emerging between the relationship between improved disability and 
increased longevity, given the current short time horizon of the registry, this has not been 
included. 
 
Table 16: Life tables for the UK population (Probability a person aged x will die before x+1) 
 Standard Adjusted for RA  (cont) Standard Adjusted for RA 
Age Male Female Male Female  Age Male Female Male Female 
0 0.0060 0.0048 0.0120 0.0097  51 0.0044 0.0029 0.0070 0.0050 
1 0.0004 0.0003 0.0009 0.0007  52 0.0048 0.0032 0.0076 0.0056 
2 0.0003 0.0002 0.0005 0.0004  53 0.0052 0.0034 0.0082 0.0059 
3 0.0002 0.0002 0.0003 0.0003  54 0.0056 0.0038 0.0090 0.0067 
4 0.0002 0.0002 0.0003 0.0003  55 0.0063 0.0041 0.0101 0.0072 
5 0.0001 0.0001 0.0003 0.0002  56 0.0072 0.0045 0.0115 0.0079 
6 0.0001 0.0001 0.0003 0.0002  57 0.0079 0.0051 0.0126 0.0089 
7 0.0001 0.0001 0.0002 0.0002  58 0.0087 0.0053 0.0140 0.0093 
8 0.0001 0.0001 0.0002 0.0002  59 0.0098 0.0060 0.0156 0.0104 
9 0.0001 0.0001 0.0002 0.0002  60 0.0110 0.0068 0.0177 0.0118 
10 0.0001 0.0001 0.0002 0.0002  61 0.0120 0.0074 0.0193 0.0129 
11 0.0001 0.0001 0.0003 0.0002  62 0.0133 0.0079 0.0212 0.0139 
12 0.0002 0.0001 0.0003 0.0002  63 0.0145 0.0087 0.0232 0.0152 
13 0.0002 0.0001 0.0004 0.0002  64 0.0157 0.0097 0.0251 0.0169 
14 0.0002 0.0001 0.0004 0.0003  65 0.0176 0.0105 0.0228 0.0158 
15 0.0003 0.0002 0.0005 0.0003  66 0.0194 0.0118 0.0252 0.0176 
16 0.0004 0.0002 0.0007 0.0005  67 0.0216 0.0130 0.0281 0.0194 
17 0.0006 0.0003 0.0011 0.0005  68 0.0237 0.0144 0.0308 0.0216 
18 0.0008 0.0003 0.0016 0.0006  69 0.0266 0.0160 0.0346 0.0241 
19 0.0008 0.0003 0.0016 0.0006  70 0.0292 0.0178 0.0380 0.0267 
20 0.0008 0.0003 0.0017 0.0006  71 0.0328 0.0202 0.0427 0.0303 
21 0.0008 0.0003 0.0016 0.0006  72 0.0366 0.0226 0.0475 0.0339 
22 0.0009 0.0003 0.0018 0.0006  73 0.0405 0.0253 0.0527 0.0380 
23 0.0008 0.0003 0.0017 0.0006  74 0.0456 0.0282 0.0592 0.0423 
24 0.0009 0.0003 0.0018 0.0006  75 0.0499 0.0316 0.0649 0.0474 
25 0.0009 0.0003 0.0014 0.0006  76 0.0549 0.0351 0.0714 0.0527 
26 0.0008 0.0004 0.0013 0.0006  77 0.0606 0.0389 0.0788 0.0584 
27 0.0009 0.0004 0.0015 0.0006  78 0.0666 0.0428 0.0866 0.0643 
28 0.0009 0.0004 0.0015 0.0006  79 0.0732 0.0472 0.0951 0.0709 
29 0.0010 0.0004 0.0016 0.0007  80 0.0797 0.0532 0.1036 0.0798 
30 0.0010 0.0004 0.0016 0.0007  81 0.0861 0.0586 0.1119 0.0878 
31 0.0010 0.0005 0.0017 0.0009  82 0.0937 0.0657 0.1218 0.0986 
32 0.0011 0.0005 0.0018 0.0009  83 0.1042 0.0731 0.1354 0.1096 
33 0.0011 0.0005 0.0017 0.0010  84 0.1170 0.0836 0.1521 0.1254 
34 0.0012 0.0006 0.0019 0.0011  85 0.1298 0.0931 0.1687 0.1396 
35 0.0012 0.0007 0.0019 0.0012  86 0.1408 0.1023 0.1831 0.1535 
36 0.0013 0.0007 0.0021 0.0012  87 0.1514 0.1136 0.1968 0.1704 
37 0.0014 0.0007 0.0022 0.0013  88 0.1674 0.1267 0.2176 0.1901 
38 0.0014 0.0008 0.0023 0.0015  89 0.1821 0.1404 0.2367 0.2106 
39 0.0016 0.0009 0.0025 0.0016  90 0.1898 0.1546 0.2468 0.2319 
40 0.0017 0.0010 0.0027 0.0017  91 0.2016 0.1710 0.2621 0.2565 
41 0.0019 0.0011 0.0030 0.0019  92 0.2235 0.1879 0.2905 0.2818 
 41 
42 0.0019 0.0012 0.0030 0.0022  93 0.2410 0.2070 0.3134 0.3105 
43 0.0021 0.0014 0.0034 0.0025  94 0.2590 0.2215 0.3367 0.3322 
44 0.0022 0.0015 0.0035 0.0026  95 0.2807 0.2420 0.3649 0.3631 
45 0.0025 0.0016 0.0040 0.0029  96 0.2971 0.2602 0.3863 0.3904 
46 0.0028 0.0019 0.0045 0.0034  97 0.3260 0.2766 0.4238 0.4149 
47 0.0032 0.0020 0.0051 0.0036  98 0.3408 0.2989 0.4430 0.4484 
48 0.0033 0.0022 0.0053 0.0038  99 0.3547 0.3177 0.4610 0.4766 
49 0.0039 0.0024 0.0062 0.0043  100 0.3869 0.3435 0.5030 0.5153 
50 0.0041 0.0027 0.0066 0.0047       
 
Table 17: Standardised Mortality Ratios for Rheumatoid Arthritis population  
Age Male  Female  
0-24 2 2 
25-64 1.6 1.75 
65+ 1.3 1.5 
WHO Global Burden of Disease programme 
 
2.13.1. Exclusion of any Biological Effect on Mortality Risk Reduction 
 
Also excluded from our analysis is any potential effect of TNF inhibitor therapies on 
mortality.  There are studies, which show a significant association between HAQ 
improvement and reduced mortality risk.  [Pincus 2001], [Yelin et al , 2002]   
 
2.14. DISCOUNTING 
 
The discount rates in the basecase are set at 6% for costs and 1.5% for QALYS in line 
with the NICE protocol (viewed using 
http://www.nice.org.uk/pdf/Final_protocol_Anti_TNF.pdf  
on 25th May 2005) and as discussed by telephone with the NICE technical lead. 
 
In a sensitivity analysis, we investigate the effects of discounting both benefits and costs 
at a 3.5% annual rate. 
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2.15. NUMBER OF RUNS REQUIRED FOR PROBABILISTIC 
SENSITIVITY ANALYSIS  
 
The model is a patient level simulation. Therefore running a probabilistic sensitivity 
analysis requires stability in both 1st and 2nd order uncertainty. We have used 
methodology recently developed in the University of Sheffield by Prof. Tony O’Hagan 
and colleagues at the Centre for Bayesian Statistics and health Economics (CHEBS) to 
quantify how many individual patient runs are necessary for stable results when 
undertaking probability sensitivity analysis. [O'Hagan et al. 2005] 
Early runs of the model suggested a 1000 patient run would give a standard error in cost 
per QALY of approximately £300 to £400.  
 
The formulae to optimise the number. of individuals sampled per 2nd order parameter 
sample gave results of 20 if cost variance were used as the metric, and 75 if QALY 
variance were used. 
 
We therefore decided to run all analyses with 100 Monte Carlo samples for analysing 
parameter uncertainty. For each sample, we undertook ran 50 hypothetical individual 
patients. A total of 5000 model runs per evaluation. 
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3. RESULTS 
3.1. BASECASE 1 – CURRENT UK PRACTICE AS PER BSRBR REGISTRY 
In the first basecase analysis we make the assumptions on evidence as set out in the 
figure below. 
Figure 10     Summary of Assumptions made in Basecase1 
Health state utility estimate
Utility Progression on Biologic after 6m
Allow age/dis dur'n update on Biologic?
Probabilistic Sensitivity Analysis
Costs to include
Number of TNFs
Discount rates 6.0%      Costs 60
1.5%      Benefits 15
Response Threshold
Keep on only Moderate / Good responders for
Keep on only Good responders for 
Withdrawal
Patient population
HAQ (0-3)
Age (yrs)
Disease duration (yrs)
Number of previous DMARDs
Gender
Combination DMARD
Treatment cost
848.5976563
HAQ progression on DMARD
Utility / HAQ relationship
On Off
Drug Monitoring Hospitalisation
Use actual data from BSRBR
0-0.5 0.5-1.0 1.0-1.5 1.5-2.0 2.0-2.5 2.5-3.0
<40
All
40-50 50-60 60-70 70+ All
0-5 5-10 10-15 15+ All
<2 <3 <4 <5 5+
Male Female All
Yes No All
Licenced BSRBR reported dose BSRBR no creep
Single use 2 in a sequence
All
Do not link to improvement Link to improvement
SF6D EQ5D
3m 6m
3m 6m
Zero BSR 6-18m data
Yes No
Scott et al ERAS II ERAS III / IV 
Group Box 227
Bansback High Low
 
 
Table 18  Results Summary Table for BaseCase1 – Current UK Practice as per BSRBR Registry 
Results Summary Table
Incremental
Mean S.E. Mean S.E. Mean
Lifetime Cost 57,919£     4,533£       20,706£     3,006£       37,214£               
Lifetime QALY 5.1514       0.5657       3.5931       0.6257       1.5583                 
Cost Per QALY gained 23,882£      
Probability that Biologic Therapy is Cost-Effective Overall EVPI per patient
at £20,000 per QALY 11%
at £30,000 per QALY 84% 309£          
TNF inhibitor  Therapy Traditional DMARDs
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The results show an estimated discounted lifetime cost of nearly £58,000 on TNF 
inhibitor therapy versus around £21,000 on traditional DMARDs.  The incremental cost 
of around £37,000 achieves an estimated discounted QALY gain of 1.5583 over a 
lifetime.  The resulting cost per QALY gained of is £23,882.  This is around the range 
which might be considered acceptable by NICE.  The probabilistic sensitivity analyses 
confirm this, showing an 84% probability of being cost-effective at a £30,000 threshold. 
 
Figure 11 Cost-Effectiveness Plane BaseCase1 – Current UK Practice as per BSRBR Registry (based 
on 100 models runs) 
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Figure 12nsitivity analyses confirm this, showing an 84% probability of being cost-effective at a 
£30,000 threshold. 
 
Figure • SEQ Figure \* ARABIC •11• Cost-Effectiveness Plane BaseCase1 – Current UK Practice 
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3.2. \* ARABIC •11• COST-EFFECTIVENESS PLANE BASECASE1 – 
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0 models runs) 
• 
Figure • SEQ Figure \* ARABIC at the rule to withdraw patients who are not achieving 
moderate DAS28 response at 3 months is applied.  This of course means that the utility 
gains achieved by the poor responders are forgone, but also that the costs of ongoing 
treatment for this group are saved. 
Table 19  Results Summary Table for BaseCase2 – Modelling the BSR Guidance – Withdrawal at 3 
months unless Moderate DAS28 Response Is Achieved 
Results Summary Table
Incremental
Mean S.E. Mean S.E. Mean
Lifetime Cost 53,884£     4,959£       20,880£     3,058£       33,004£               
Lifetime QALY 4.9634       0.5392       3.4885       0.6018       1.4749                 
Cost Per QALY gained 22,378£      
Probability that Biologic Therapy is Cost-Effective Overall EVPI per patient
at £20,000 per QALY 20%
at £30,000 per QALY 95% 120£          
TNF inhibitor  Therapy Traditional DMARDs
 
 
 
The result is a discounted lifetime cost reduction of around £4,000 on TNF inhibitor 
therapy, when compared with Basecase1.  The incremental cost of around £33,000 
achieves an estimated discounted lifetime QALY gain of 1.4749  (0.0834 lower than 
basecase1).  The resulting cost per QALY gained of £22,378 is 7% lower than that for 
basecase 1.   
 
PSA results show a 95% probability of being below a £30k threshold. 
 
Figure 13 Cost-Effectiveness Plane BaseCase2 – Modelling the BSR Guidance – Withdrawal at 3 
months unless Moderate DAS28 Response Is achieved (based on 100 models runs) 
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Figure 14 Cost-Effectiveness Acceptability Curve for BaseCase2 – Modelling the BSR Guidance – 
Withdrawal at 3 months unless Moderate DAS Response Is achieved (based on 100 models runs) 
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3.3. IMPACT OF DISCOUNTING ASSUMPTIONS (3½% COSTS, 3½% 
QALYS) 
 
When NICE made the decision to recommend TNF-α treatments for RA, the mechanism 
for valuing long-term benefits and cost used a discount rate for costs of 6% and for 
benefits of 1.5%.   
 
It has been agreed for the purposes of the 2005 NICE appraisal that these discount rates 
will again be used. 
 
However, recent guidance suggests that discount rates of 3.5% should be used for both 
costs and benefits.  This has important implications for treatments of chronic conditions 
where the system is ‘buying’ improvements in quality of life several years from now. 
 
For example under the current assumptions (1.5% discounting) a year of full perfect 
health (i.e. 1 QALY) in 2015 would be 0.8533 discounted QALYs, whereas the 
suggested new assumptions on discount rates imply its value is just 0.6879 – a 20% 
reduction in the value of future benefits in 10 years.  The effect accelerates over time so 
that in 20 years the equivalent reduction in the value of long-term health gains is 34%. 
 
3.3.1. Impact of Discounting Assumptions On BaseCase1 
Table 20: BaseCase 1 Sensitivity– Impact of Discounting Assumptions (3.5% costs, 3.5% QALYs) 
 
Results Summary Table         
  TNF inhibitor  Therapy Traditional DMARDs Incremental 
 Mean S.E. Mean S.E. Mean 
Lifetime Cost   £    72,545   £     5,513   £    31,199   £     4,054   £            41,346  
Lifetime QALY       4.2843        0.4319        2.9927        0.5685                 1.2916  
Cost Per QALY gained          £    32,013  
      
Probability that Biologic Therapy is Cost-Effective Overall EVPI per patient 
at £20,000 per QALY  0%    
at £30,000 per QALY   36%    £     1,595    
  
 
The results of analysis using 3.5% and 3.5% discount rates, show a cost per QALY 
gained of around £32,000, suggesting that anti-TNF-α therapies would be considered on 
the borderline of cost-effective if a £30k willingness to pay for QALYs threshold were 
applied by decision makers.  The probabilistic sensitivity analyses under these 
assumptions suggest a 36% probability of being below the £30k threshold . 
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Figure 15 Cost-Effectiveness Plane Sensitivity Analysis– Impact of Discounting Assumptions (based 
on 100 models runs) 
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Figure 16 Cost-Effectiveness Acceptability Curve for Sensitivity Analysis– Impact of Discounting 
Assumptions (based on 100 models runs) 
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3.3.2. Impact of Discounting Assumptions On BaseCase2 
 The results of using 3.5% discount rates (for both costs and QALYs) in basecase 2 are 
similar. 
 
Table 21 Basecase2 Sensitivity– Impact of Discounting Assumptions (6% costs, 1.5% QALYs) 
Results Summary Table         
  
TNF inhibitor  
Therapy Traditional DMARDs Incremental 
 Mean S.E. Mean S.E. Mean 
Lifetime Cost  
 £    
68,075  
 £     
6,403  
 £    
30,443  
 £     
5,163  
 £            
37,632  
Lifetime QALY 
      
4.2906  
      
0.4914  
      
3.0838  
      
0.5641  
               
1.2068  
Cost Per QALY 
gained          £    31,184  
      
Probability that Biologic Therapy is Cost-Effective Overall EVPI per patient 
at £20,000 per QALY  0%    
at £30,000 per QALY   43%   
 £     
1,834    
  
Figure 17 Cost-Effectiveness Plane Sensitivity Analysis– Impact of Discounting Assumptions  
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Figure 18 CEAC Analysis– Impact of Discounting Assumptions 
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3.4. IMPACT OF USING SF-6D DERIVED UTILITY  
The BSRBR data recorded quality of life data using the SF36 questionnaire.  This can be 
translated into health state utilities via the SF6D algorithm as described in 2.1.5. 
However, as detailed earlier, this instrument suffers from a ‘floor-effect’ in patients with 
severe diseases, whereby patients below a certain level of disability are not well 
discriminated by the SF36 questionnaire.  If decision makers were to choose to believe 
the validity of SF6D based results the effects would be substantial. 
 
Table 22 BaseCase1 Sensitivity Analysis– Impact of Using SF36 Derived Utility 
 
Results Summary Table         
  TNF inhibitor  Therapy Traditional DMARDs Incremental 
 Mean S.E. Mean S.E. Mean 
Lifetime Cost   £    61,382   £     4,075   £    22,978   £     3,162   £            38,405  
Lifetime QALY       8.6342        0.6899        7.8375        0.6637                 0.7967  
Cost Per QALY gained          £    48,206  
      
Probability that Biologic Therapy is Cost-Effective Overall EVPI per patient 
at £20,000 per QALY  0%    
at £30,000 per QALY   0%    £          -     
  
The incremental QALY gained by TNF inhibitor therapy is almost halved if the SF6D 
derived utility is used rather than the EQ5D instrument.  The result is a cost per QALY 
that is around double the basecase. 
Figure 19 Cost-Effectiveness Plane Sensitivity Analysis– Impact of SF6D Utility on BaseCase1 
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Figure 20 Cost-Effectiveness Acceptability Curve for Sensitivity Analysis– Impact of Using SF36 
Derived Utility (based on 100 models runs) 
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3.5. IMPACT OF DISABILITY PROGRESSION RATE WHILST ON DMARDS 
 
The basecase analysis assumes that disability progression whilst on traditional DMARDs 
is best estimated by the weighted average of the studies examined by Scott et al. (Table 
9).  The resulting progression rate assumed was 0.0418 HAQ points per annum.  The 
individual studies examined by Scott et al. show some substantial differences. 
 
The question arises as to what is the relevant rate for patients who currently receive TNF 
inhibitor therapy in the UK i.e. what would their progression be in the absence of TNF 
inhibitor therapy.  Unfortunately there are too few patients followed for too short a time 
in the BSRBR control arm to provide any useful evidence for this long-term progression.   
 
Previous analyses examined the Early Rheumatoid Arthritis Study data to make some 
estimates of this (Brennan et al.)  In sensitivity analyses here, we examine the impact of 
alternative assumptions on HAQ progression for the control arm and the TNF inhibitor 
arm after TNF inhibitor withdrawal. 
 
We must note too that, in the absence of data to undertake covariate adjustment, the 
progression rate is assumed equivalent for every patient subgroup within our model.  
Thus patients who have failed several DMARDs even whilst quite young are assumed to 
have the same rate of HAQ progression as those who have had only 2 or 3 DMARDs 
over more than 15 years. 
 
3.5.1. Sensitivity On Disability Progression in Basecase1 - ERAS data on 
Patients who have failed 2 DMARDs (worsening = 0.07 HAQ points per 
annum) 
Table 23 Basecase1 Sensitivity Analysis– Impact of Using ERAS data on Patients who have failed 2 
DMARDs (worsening = 0.07 per annum) 
Results Summary Table         
  TNF inhibitor  Therapy Traditional DMARDs Incremental 
 Mean S.E. Mean S.E. Mean 
Lifetime Cost   £    57,695   £     3,954   £    20,898   £     2,927   £            36,797  
Lifetime QALY       4.4602        0.5731        2.4752        0.6452                 1.9850  
Cost Per QALY gained          £    18,537  
      
Probability that Biologic Therapy is Cost-Effective Overall EVPI per patient 
at £20,000 per QALY  68%    
at £30,000 per QALY   100%    £          -     
  
If a HAQ progression rate on traditional DMARDs were 0.07 points per annum then the 
cost per QALY gained by TNF inhibitor therapies would be around £18,500. 
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The PSA analyses would then suggest a 100% probability of being under the £30k 
threshold) 
Figure 21 Cost-Effectiveness Plane Sensitivity Analysis– Impact of 0.07 pa HAQ progression 
assumption on Basecase1 
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Figure 22 Cost-Effectiveness Acceptability Curve for Sensitivity Analysis– Impact of Using ERAS 
data on Patients who have failed 2 DMARDs (worsening = 0.07 per annum) 
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3.5.2. Sensitivity On Disability Progression in Basecase1 - ERAS data on 
Patients in Functional Class III/IV (worsening = 0.13 HAQ points per 
annum) 
Table 24 Basecase 1 Sensitivity– Impact of ERAS Functional Class III/IV ( 0.13 per annum) 
Results Summary Table         
  TNF inhibitor  Therapy Traditional DMARDs Incremental 
 Mean S.E. Mean S.E. Mean 
Lifetime Cost   £    58,118   £     4,243   £    21,384   £     2,990   £            36,734  
Lifetime QALY       3.2364        0.6397        0.3320        0.7059                 2.9044  
Cost Per QALY gained          £    12,648  
      
Probability that Biologic Therapy is Cost-Effective Overall EVPI per patient 
at £20,000 per QALY  100%    
at £30,000 per QALY   100%    £          -     
  
 The results if patients were progressing at a very high rate of 0.13 HAQ points per 
annum would be around £12,500 per QALY. 
 
In such circumstances, the PSA suggests 100% probability of cost-effectiveness at both 
£30,000 and £20,000 thresholds. 
 
Figure 23 C-E Plane– Impact of 0.13 pa HAQ progression on BaseCase1 (note rescaled axes) 
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Figure 24 CEAC– Impact of Using ERAS Functional Class III/IV (worsening = 0.13 per annum) 
 
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
90.00%
100.00%
£0 £10,000 £20,000 £30,000 £40,000 £50,000 £60,000 £70,000 £80,000 £90,000 £100,000
Cost effectiveness threshold (λ)
Pr
ob
ab
ili
ty
 c
os
t e
ffe
ct
iv
e 
 
 
 59 
3.5.3. Sensitivity On Disability Progression in Basecase2 
 
The equivalent sensitivity analyses using alternative data for disability progression on 
DMARDs from the ERAS database give slightly lower cost per QALY when applied to 
Basecase2. 
 
Table 25  Basecase 2 Sensitivity– Impact of Using ERAS data on (a) Patients who have failed 2 
DMARDs (worsening = 0.07 per annum) and (b) Functional Class III/IV ( 0.13 per annum) 
Part a - Patients who have failed 2 DMARDs (worsening = 0.07 per annum) 
 
Results Summary Table         
  
TNF inhibitor  
Therapy Traditional DM ARDs Incremental 
 Mean S.E. Mean S.E. Mean 
Lifetime Cost  
 £    
53,131  
 £     
4,686  
 £    
20,971  
 £     
2,708  
 £            
32,160  
Lifetime QALY 
      
4.3928  
      
0.6572  
      
2.6122  
      
0.6414  
               
1.7807  
Cost Per QALY 
gained          £    18,061  
      
Probability that Biologic Therapy is Cost-Effective Overall EVPI per patient 
at £20,000 per QALY  76%    
at £30,000 per QALY   100%    £          -     
  
 
 
Part b - Functional Class III/IV ( 0.13 per annum) 
 
Results Summary Table         
  
TNF inhibitor  
Therapy Traditional DMARDs Incremental 
 Mean S.E. Mean S.E. Mean 
Lifetime Cost  
 £    
54,426  
 £     
4,974  
 £    
21,463  
 £     
3,269  
 £            
32,963  
Lifetime QALY 
      
2.9544  
      
0.7025  
      
0.3086  
      
0.8421  
               
2.6458  
Cost Per QALY 
gained          £    12,459  
      
Probability that Biologic Therapy is Cost-Effective Overall EVPI per patient 
at £20,000 per QALY  100%    
at £30,000 per QALY   100%    £          -     
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3.6. SUMMARY OF SENSITIVITY ANALYSES UNDERTAKEN ON 
BASECASE1 
 
Table 26 sets out the results for all of the sensitivity analyses undertaken on basecase 1. 
The analyses discussed earlier on SF6D, HAQ progression and discounting are presented 
in the table as analyses 1b, 1c, 3 and 6.   
 
3.6.1.  Utility Relationship with HAQ (Analysis 2a) 
 
Previous work undertaken by Birmingham assessing cost effectiveness of TNF inhibitors 
used an assumption that utility was related to HAQ disability score with a linear slope of 
–0,3.  If this assumption is used the cost per QALY is around £20,000 (a 16% reduction 
as compared with the basecase). 
 
3.6.2. Two TNF inhibitors in sequence (Analysis 5) 
 
When we have analysed the use of 2 TNF inhibitors in sequence, making the assumption 
that the probability of response and utility gained following a switch to a second TNF 
inhibitor are able to be modelled using the same relationships as seen from the BSRBR 
data, then we find the results only marginally different from the basecase (cost per QALY 
increased by just 2%). 
 
3.6.3. Withdrawal assumptions based on BSR guidance (Analyses 7,8) 
 
Current guidance suggests that patients now achieving moderate response should 
withdraw at 3 months.  If this policy (7a) were implemented it would reduce the overall 
costs of the overall lifetime costs by around 7%, whilst reducing the overall QALY gain 
by around 4%.  This results in a cost per QALY of around £22,000 (7% lower than the 
basecase). 
 
Withdrawal at 3 months if good response is not achieved (7b) has much more substantial 
effect on cost reductions but also reduces the QALY gain and produces a cost per QALY 
of the same order of around £23,000 per QALY. 
 
The implementation of the stopping rules at 3 or 6 months as set out above, does not have 
as big an impact on cost effectiveness as the authors expected a priori.  The main reason 
for this is that there is some utility gain obtained for those persons who do not achieve 
moderate response i.e., even patients achieving poor response on average improved their 
utility (see table 12d in appendix 1, section 6.1). 
 
Sensitivity Analysis 8, which examines a rule to withdraw any patient whose utility 
actually worsens make little difference to the results. 
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Table 26 Summary of All Sensitivity Analyses Undertaken On BaseCase1 
    TNF 
inhibitor 
Cost 
DMARD 
Cost 
TNF 
inhibitor 
QALY 
DMARD 
QALY 
Incremental 
Cost 
Incremental 
QALY 
Cost Per 
QALY gained 
%Diff in 
CPerQ from 
Basecase 
%<20k %<30k Overall 
EVPI per 
person at 
£30k 
BaseCase1  £  57,919   £  20,706  5.1514   3.5931   £  37,214       1.5583   £     23,882  0% 11% 84%  £     309  
Sensitivity Analysis  <--------------% Difference from BaseCase1------------------>   <--------------Result Summary---------------->  
1c HAQ 0.13pa 0% 3% -37% -91% -1% 86%  £   12,648  -47% 100% 100%  £-    
1b HAQ 0.07pa -0% 1% -13% -31% -1% 27%  £   18,537  -22% 68% 100%  £-    
2a Utility per HAQ -0.3 1% 2% -7% -18% 0% 19%  £   20,016  -16% 48% 99%  £      8  
2b Utility per HAQ -0.1 -0% -3% 8% 19% 1% -18%  £   29,503  24% 0% 59%  £2,032  
3 SF36 6% 11% 68% 118% 3% -49%  £   48,206  102% 0% 0%  £-    
4 Age/DisDur Increase 1% 2% -3% 0% 0% -9%  £   26,428  11% 2% 75%  £   818  
5 2 TNF inhibitors In Sequence 11% 3% 5% 1% 16% 14%  £   24,328  2% 9% 88%  £   462  
6 Discount (3.5%,3.5%) 25% 51% -17% -17% 11% -17%  £   32,013  34% 0% 36%  £1,595  
7a Withdraw at 3m if not moderate -7% 1% -3% -3% -11% -4%  £   22,203  -7% 20% 97%  £   106  
7b Withdraw at 6m if not moderate -7% 1% -2% 0% -11% -8%  £   23,084  -3% 14% 93%  £   148  
7c Withdraw at 3m if not good -39% 1% -19% -1% -61% -59%  £   22,476  -6% 26% 87%  £   333  
7d Withdraw at 6m if not good -39% 2% -19% -2% -61% -59%  £   22,316  -7% 30% 85%  £   348  
8 Withdraw if Utility Worsens -2% 2% 3% 6% -5% -4%  £   23,824  -0% 10% 88%  £   347  
9a Baseline HAQ = [0.0 to 0.5] 2% -14% -35% -99% 11% 112%  £   12,524  -48% 100% 100%  £-    
9b Baseline HAQ = [0.5 to 1.0] 3% -6% 82% 121% 8% -7%  £   27,863  17% 0% 66%  £1,391  
9c Baseline HAQ = [1.0 to 1.5] 4% 2% 62% 90% 6% -4%  £   26,306  10% 3% 74%  £   816  
9d Baseline HAQ = [1.5 to 2.0] 1% 3% -6% -11% -1% 3%  £   22,962  -4% 22% 93%  £   317  
9e Baseline HAQ = [2.0 to 1.5] 3% 1% 41% 56% 4% 6%  £   23,433  -2% 14% 93%  £   208  
9f Baseline HAQ = [2.5 to 3.0] -4% 1% -47% -65% -7% -6%  £   23,695  -1% 8% 92%  £   148  
10a Age <40 9% 5% 68% 71% 11% 63%  £   16,252  -32% 94% 100%  £-    
10b Age 40 to 50 8% 6% 23% 18% 9% 36%  £   19,057  -20% 67% 99%  £       6  
10c Age 50 to 60 2% 1% 3% 3% 3% 4%  £   23,444  -2% 18% 91%  £   350  
10d Age 60 to 70 -6% -2% -32% -35% -9% -25%  £   29,147  22% 0% 56%  £1,702  
10e Age 70+ -19% -9% -58% -61% -25% -51%  £   36,312  52% 0% 19%  £   598  
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11a Disease Duration 0 to 5 yrs 0% -7% 29% 33% 4% 21%  £   20,581  -14% 42% 100%  £-    
11b Disease Duration 5 to 10 yrs -1% -1% 13% 15% -0% 7%  £   22,207  -7% 20% 95%  £   167  
11c Disease Duration 10 to 15 yrs 2% 2% 3% 1% 2% 8%  £   22,633  -5% 15% 93%  £   224  
11d Disease Duration 15+ yrs -1% -0% -15% -19% -1% -6%  £   25,310  6% 9% 79%  £   758  
12a Previous DMARDs <2 -0% -8% 27% 26% 4% 31%  £   18,949  -21% 67% 100%  £-    
12b Previous DMARDs <3 1% -9% 30% 35% 6% 18%  £   21,585  -10% 29% 99%  £     26  
12c Previous DMARDs <4 -0% -6% 17% 20% 2% 8%  £   22,585  -5% 17% 95%  £   113  
12d Previous DMARDs <5 -3% -4% -6% -7% -2% -4%  £   24,438  2% 8% 86%  £   634  
12e Previous DMARDs 5+ 2% 9% -10% -13% -2% -5%  £   24,628  3% 5% 90%  £   300  
13a Gender = Male -5% 4% -16% -16% -10% -17%  £   25,998  9% 1% 80%  £   603  
13b Gender = Female -0% -0% -1% -3% -0% 3%  £   23,193  -3% 16% 89%  £   439  
14a TNF inhibitor + Combination 
DMARD  6% 4% -1% 1% 7% -5%  £   27,111  14% 1% 76%  £1,051  
14b TNF inhibitor Monotherapy -0% 3% 1% 2% -2% 1%  £   23,280  -3% 12% 91%  £   291  
15a Dose as per BSRBR reported 18% -2% -1% -3% 28% 2%  £   29,999  26% 0% 53%  £3,215  
15b Dose without Dose Creep 18% 2% 0% 1% 27% -0%  £   30,263  27% 0% 47%  £2,712  
16a Use BSR Utility prog'n long-tem 0% 1% -23% -3% -1% -71%  £   82,471  245% 0% 3%  £   141  
16b Use BSR Utility prog'n till 18m 1% 2% -7% -5% 1% -12%  £   27,477  15% 3% 69%  £1,352  
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3.6.4. Subgroup analysis by baseline HAQ score (Analysis 9) 
 
Analyses 9a to 9f show that patients with a higher baseline HAQ score on average 
achieve slightly better cost effectiveness (i.e. lower cost per QALY gain) . For example 
the baseline HAQ subgroup [2.5 to 3.0] has a cost per QALY of approximately £24,000 
whilst the group baseline HAQ = [0.5 to 1.0] has a cost per QALY of around£27,000.  
NOTE the results for baseline HAQ [0.0 to 0.5] (9a) should be ignored as it is based on 
less than 5 individual patients in the database. 
 
3.6.5. Age subgroups  (Analysis 10) 
 
The age subgroup analysis suggests that it is significantly more cost effective to treat 
patients at a younger age.  For example the cost per QALY for patients aged 70+ is over 
£36,000 whereas the cost per QALY for patients under 40 is around£16,000.  This is 
because patients at a younger age live for a longer time and therefore have more time to 
accrue the long-term benefits of TNF inhibitor therapy in terms of delayed disease 
progression. 
 
3.6.6. Disease duration sub groups. (Analysis 11) 
 
Treating patients with shorter disease duration appears slightly more cost effective than 
treating those with longer disease duration.  The cost per QALY for patients in the 
subgroup disease duration 0 to 5 years is around£20,000.  Whereas for a disease duration 
of over 15 years, the cost per QALY is around£25,000.  This is probably because disease 
duration is partly correlated with age. 
 
3.6.7. Sub group analysis based on previous DMARD use (Analysis 12). 
 
The analyses show that the number of previous DMARDS makes a marginal difference 
and that treating patients with fewer DMARDS is slightly more cost effective than those 
who have previously used 5+ DMARDS.  Again this is probably because the probability 
of improvement and the level of initial improvement is slightly lower as the number of 
previous DMARDS increases. Again patients with fewer DMARDS will also on average 
have slightly lower age. 
 
3.6.8. Male versus female (Analysis 13) 
 
Subgroups based on gender alone make very little different to the results with males 
marginally less cost effective than females. 
 
NOTE, one caution on this analysis is that we have assumed, at this stage, an average 
weight of 70kg for each patient.  For infliximab based therapy costs are proportional to 
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weight and therefore larger differences may occur between males and females were this 
to be taken into account. 
 
3.6.9. Combination or monotherapy (Analysis 14) 
 
TNF inhibitor plus combination DMARD therapy patients has a slightly higher cost per 
QALY (around£27,000) as compared with those on monotherapy (around£23,000). 
 
As discussed in section 2.10.1 on methods, there are some important caveats around the 
reported dose data in the BSRBR data.  If we make a worse case assumption that these 
doses are all correct then the cost per QALY would increase substantially to 
around£30,000. 
 
3.6.10. Utility progression from 6 months onward (Analysis 16) 
 
In the basecase analysis we have assumed that successful responders to therapy maintain 
their level of utility until such time as they withdraw from therapy, i.e. the rate of utility 
progression from 6 months onwards is 0.  Some BSRBR data does exist on utility 
progression. There are several caveats around it, including in particular, that it is 
relatively short term with not many patients followed beyond 18 months. 
 
At this stage we have analysed the data using one simple covariate, (DAS28 response 
level achieved at 6 months) rather that the more complex set of covariates set out in other 
statistical analyses. The results suggest that patients achieving good response by 6 
months have a marginal worsening of utility over 6 to 18 months.  Moderate DAS28 
responders have a utility progression of approximately 0 and the poor DAS28 responders 
actually have a continued utility gain.  If we utilise these data over 6 to 18 months and 
then apply an assumption that patients have zero utility progression from then onwards, 
the cost per QALY would be approximately 15% higher at around £27,500 (analysis 
16b). 
 
If we were to assume that these data actually applied long term then the cost effectiveness 
would be around £80,000.  This latter analysis is nonsensical because it soon becomes 
apparent that, after a number of years, patients who have had initially poor response have 
had a much higher level of utility (because they are assumed to continue with a linear 
upwards progression) than those who initially had a very good response who are 
progressing marginally downwards. 
 
3.6.11. Cautions upon all the sensitivity analyses in basecase 1 
 
It must be remembered in interpreting these analyses that the absolute result is less 
important than the change from baseline.  For example, if the true level of HAQ 
progression on DMARD therapy were 0.07 per annum, then we would re-base the 
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basecase to around £18,500 per QALY and all of the sensitivity analyses would occur 
around this basecase. 
 
It should also be noted that: 
a. we have modelled TNF inhibitors as a class and not disentangled Etanercept 
from Infliximab or Adalimumab. 
b. We have assumed an average weight per patient of 70kg. 
c. All of the assumptions set out in the methods section apply. 
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3.7. SENSITIVITY ANALYSES ON BASECASE2 
 
A similar set of sensitivity analyses have been undertaken on basecase 2 and are reported 
below. 
 
The resulting effects are all of the same order as those shown for basecase 1. 
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Table 27 Summary of All Sensitivity Analyses Undertaken On Basecase 2 
    TNF 
inhibitor 
Cost 
DMARD 
Cost 
TNF 
inhibitor 
QALY 
DMARD 
QALY 
Incremental 
Cost 
Incremental 
QALY 
Cost Per 
QALY gained 
%Diff in 
Cost Per 
QALY from 
BaseCase 
%<20k %<30k Overall 
EVPI per 
person at 
£30k 
BaseCase2  £ 53,884   £ 20,880  4.9634  3.4885   £  33,004  1.4749   £  22,378  0% 20% 95%  £         120  
Sensitivity Analysis  <-------------------Difference from BaseCase1------------------------->   <-------------------Result Summary------------------>  
1c HAQ 0.13pa 1% 3% -40% -91% -0% 79%  £   12,459  -44% 100% 100%  £-    
1b HAQ 0.07pa -1% 0% -11% -25% -3% 21%  £   18,061  -19% 76% 100%  £-    
2a Utility per HAQ -0.3 -0% 4% -8% -18% -2% 15%  £   19,026  -15% 62% 99%  £     11  
2b Utility per HAQ -0.1 1% -1% 11% 24% 2% -17%  £   27,680  24% 0% 70%  £1,370  
3 SF36 7% 13% 73% 125% 3% -48%  £   44,174  97% 0% 0%  £-    
4 Age/DisDur Increase 0% -0% -2% 1% 1% -8%  £   24,507  10% 9% 84%  £   512  
5 2 TNF inhibitors In Sequence 17% 1% 6% -1% 27% 23%  £   23,036  3% 18% 94%  £   459  
6 Discount (3.5%,3.5%) 26% 46% -14% -12% 14% -18%  £   31,184  39% 0% 43%  £1,834  
7a Withdraw at 3m if not moderate 0% 0% 0% 0% 0% 0%  £   22,378  0% 20% 95%  £   120  
7b Withdraw at 6m if not moderate 1% -1% 3% 4% 2% 0%  £   22,733  2% 23% 91%  £   386  
7c Withdraw at 3m if not good -32% 1% -12% 5% -53% -52%  £   21,610  -3% 34% 86%  £   275  
7d Withdraw at 6m if not good -34% -0% -18% -4% -56% -52%  £   20,670  -8% 43% 93%  £   114  
8 Withdraw if Utility Worsens -2% -1% 3% 7% -3% -6%  £   23,266  4% 13% 94%  £   212  
9a Baseline HAQ = [0.0 to 0.5] 5% -18% -38% -103% 19% 117%  £   12,283  -45% 100% 100%  £-    
9b Baseline HAQ = [0.5 to 1.0] 6% -7% 87% 125% 13% -3%  £   26,174  17% 1% 77%  £   887  
9c Baseline HAQ = [1.0 to 1.5] 6% 2% 66% 96% 9% -6%  £   25,872  16% 5% 77%  £   894  
9d Baseline HAQ = [1.5 to 2.0] 2% 2% -4% -6% 1% 0%  £   22,657  1% 21% 91%  £   191  
9e Baseline HAQ = [2.0 to 1.5] 4% -0% 45% 60% 7% 8%  £   22,199  -1% 18% 98%  £     83  
9f Baseline HAQ = [2.5 to 3.0] -6% -1% -47% -62% -9% -9%  £   22,470  0% 17% 93%  £   253  
10a Age <40 13% 2% 78% 82% 21% 68%  £   16,056  -28% 95% 100%  £-    
10b Age 40 to 50 8% 6% 24% 22% 8% 29%  £   18,839  -16% 72% 100%  £-    
10c Age 50 to 60 1% 1% 4% 7% 1% -2%  £   22,933  2% 20% 97%  £   133  
10d Age 60 to 70 -6% -4% -27% -28% -7% -26%  £   28,133  26% 1% 69%  £1,259  
10e Age 70+ -23% -10% -58% -60% -31% -54%  £   33,589  50% 1% 26%  £   632  
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11a Disease Duration 0 to 5 yrs 2% -6% 30% 34% 6% 21%  £   19,613  -12% 54% 100%  £-    
11b Disease Duration 5 to 10 yrs -0% -2% 15% 20% 1% 4%  £   21,672  -3% 32% 97%  £   119  
11c Disease Duration 10 to 15 yrs 3% 5% 4% 4% 1% 5%  £   21,566  -4% 34% 96%  £   120  
11d Disease Duration 15+ yrs 0% -0% -12% -14% 0% -8%  £   24,408  9% 11% 86%  £   624  
12a Previous DMARDs <2 1% -10% 32% 34% 8% 28%  £   18,811  -16% 64% 100%  £-    
12b Previous DMARDs <3 1% -9% 32% 42% 7% 11%  £   21,750  -3% 28% 98%  £     58  
12c Previous DMARDs <4 0% -7% 18% 22% 5% 10%  £   21,261  -5% 29% 99%  £ 2  
12d Previous DMARDs <5 -2% -2% -3% -2% -1% -5%  £   23,183  4% 17% 90%  £   244  
12e Previous DMARDs 5+ 1% 6% -12% -15% -2% -4%  £   22,935  2% 12% 94%  £   146  
13a Gender = Male -7% 0% -16% -15% -11% -17%  £   24,063  8% 10% 91%  £   312  
13b Gender = Female 1% -0% 3% 2% 2% 3%  £   22,139  -1% 24% 97%  £     23  
14a TNF inhibitor + Combination 
DMARD  6% 3% 0% 2% 8% -3%  £   24,879  11% 3% 88%  £   191  
14b TNF inhibitor Monotherapy -0% -1% 3% 3% 0% 3%  £   21,685  -3% 27% 96%  £   127  
15a Dose as per BSRBR reported 18% 1% 0% 0% 28% -0%  £   28,838  29% 0% 66%  £1,926  
15b Dose without Dose Creep 20% 1% -1% -3% 32% 5%  £   27,973  25% 1% 67%  £1,301  
16a Use BSR Utility prog'n long-tem 0% 1% -25% 5% -0% -93%  £ 335,680  1400% 0% 0%  £-    
16b Use BSR Utility prog'n till 18m 2% 3% -2% 5% 1% -20%  £   28,143  26% 3% 65%  £1,605  
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4. DISCUSSION 
4.1. CONCLUSIONS 
 
A cost-effectiveness model based on data from the British Society for Rheumatology 
Biologics Registry Modelling has been constructed. 
 
The objective of the study was to assess the cost effectiveness of anti-TNF-a inhibitors 
in the management of RA in the UK and in particular analyse: 
- What is the incremental cost utility (cost per QALY) of TNF-α inhibitors 
according to current practice in the UK versus use of traditional DMARDs only? 
- What would be the cost utility if guidance that only patients achieving moderate 
or good EULAR Disease Activity Score (DAS28) response are allowed to 
continue TNF inhibitor therapy after 3 months?  
- We also explore the use of a 2nd TNF antagonist in a sequence after the first has 
failed, based on a small amount of data 
- What is the cost utility for subgroups based on Age, Sex, Disease duration, 
Number of previous DMARDs, Baseline HAQ disability score? 
- What is the cost utility if we made alternative assumptions concerning 
interpretation of the evidence base, including those on HAQ disability 
progression on traditional DMARD, relationships between HAQ and utility, 
impact of delayed progression whilst on TNF inhibitors, use of sequential TNF 
inhibitors, and discounting rates? 
 
It should be remembered that the conclusions presented here are dependent on the 
methodology and assumptions described in section 2 of this report.  
 
 
1. The results of our analysis suggest that the cost-effectiveness of current practice 
appears around £24,000 per QALY. It is difficult to apply one basecase, so 
instead we present a number of scenarios. If the guidelines set out by NICE in 
their initial appraisal were strictly adhered to, and non-responders were 
withdrawn from therapy, this would reduce to around £22,000.   
 
2. These numbers are within the region that NICE deemed cost effective in the 
previous appraisal (‘the incremental cost-effectiveness ratio of these therapies 
(etanercept and infliximab) can be estimated to be in the region of £27,000 to 
£35,000 per QALY’. [NICE FAD, 4.2.5] 
 
3. The assessment of cost effectiveness in the 2001 appraisal was made using rates 
of discounting set at 6% cost, 1½ QALY. These still apply in the 2005 appraisal 
but new recommendations are coming (3½ % cost, 3½ QALY). The impact of 
this on the longer-term benefits make a substantial difference to the discounted 
cost per QALY gained. If the suggested new discount rates were used then the 
cost effectiveness of the TNF inhibitors are estimated to be £31,000-32,000 per 
QALY.    
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4. Assumptions concerning the long-term disease progression on traditional 
DMARDs (i.e. the control arm) also make a substantial difference to cost-
effectiveness.  The basecase analysis (Scott et al. data for the average UK 
progression) may be under-estimate.  Treatment of patients with higher rates of 
progression is much more cost-effective.  
 
5. If SF6D data were held to be a valid measure of quality of life improvements in 
severely disabled RA patients, then TNF inhibitors are estimated to have a much 
higher cost-effectiveness (almost £50,000 per QALY).  The authors view is that 
EQ5D (used in the basecase) is a more sensitive and reliable measure for 
patients with severe RA. 
 
6. Other sensitivity analyses show that patients who are younger (and have more 
lifetime in which to benefit from improved disability), have higher baseline 
disability, and fewer previous DMARDs appear slightly more cost-effective.  
 
7. Sequential therapy with 2 TNF inhibitors appears to have the same order of cost-
effectiveness as single therapy but the analysis undertaken assumes (in the 
absence of evidence on correlation) that response to a 2nd TNF inhibitor is 
independent of response to the first. 
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4.2. LIMITATIONS, FURTHER ANALYSES AND POSSIBLE RESEARCH 
IMPLICATIONS 
 
There are several caveats, limitations, and implications for possible further research, the 
most important of which are: 
 
a) The analysis has attempted to account for any selection bias between the TNF 
inhibitor and control arms in the BSRBR data by adjusting many of the 
parameters based on the main covariates.  There are sometimes limitations to 
this approach . Further analyses using propensity methods might be valuable . 
 
b) The analysis views the TNF inhibitor therapies (infliximab, etanercept and 
adalimumab) as a class rather than disentangling each individual therapy. A 
number of potential selection biases, mainly down to availability of treatment 
over the first 4 years of use make fair adjustments difficult. With additional data, 
this may become possible. 
 
 
c) The data on doses used in the BSRBR database require some caution in 
interpretation and our basecase analysis assumed standard recommended doses. 
A more detailed analysis of some fields collected in the BSRBR, in particular 
regarding the dosages of treatment would be useful. Sensitivity analysis 
demonstrated that this is a potentially sensitive variable to the cost effectiveness 
of treatment 
 
d) Costings for the ‘class’ of TNF inhibitors were based on a weighted average of 
TNF inhibitor use in the BSRBR data.  The standard cost for infliximab assumed 
a patient weight of 70kg. We did not include the cost of wastage.  A survey of 
what happens to surplus infliximab might also be useful.  
 
e) The worsening in quality of life utility over time, caused by the progression in 
radiographic damage and subsequent disability on patients taking both TNF 
inhibitors and traditional DMARDs are important parameters in the model. 
While the parameter in the model is applied equally to all patients in the control 
arm, different rates might effect the delayed progression and change the 
incremental cost effectiveness.  An investigation of data sources, which might 
enable a covariate adjustment model for this parameter, would probably be 
worthwhile to populate the parameter for patients in DMARD therapy. This 
would require long-term data on patients using conventional DMARD therapy, 
with fields such as disease duration HAQ, age and sex recorded. 
 
f) A similar covariate adjustment for duration of traditional DMARD therapy 
before withdrawal might also be useful. This would require similar data, but also 
the response to treatment. 
 
g) To understand the long-term progression of HAQ and utility whilst on TNF 
inhibitor treatment, ongoing collection of HAQ-DI score will be vital for registry 
patients.  This opposes current plans to stop collection after 5 years. 
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h) While the SF36 as collected by the BSRBR will be of some use for the 
evaluation of quality of life in patients taking TNF inhibitors, it is not the most 
appropriate instrument for obtaining health state utility values in severe RA. The 
introduction of the EQ5D (5 questions) might be of value from a health 
economic perspective. 
 
i) Excluded from our analysis is any potential effect of TNF inhibitor therapies on 
mortality.  There are studies, which show a significant association between HAQ 
improvement and reduced mortality risk. Again, evidence in the next few years 
from the BSRBR will allow for this examination. 
 
j) We have not examined the costs, or the quality of life impact, of individual 
adverse events. More detailed analysis, particularly on chronic events would be 
helpful in future evaluations.   
-  
k) Detailed costing of hospitalisations are probably under-estimated because 
patients about to receive joint surgery for example may not have started TNF 
inhibitor therapy. Ongoing data collection on hospitalisations would also be 
valuable. 
 
l) Any mortality reduction benefits, which might be attributable to TNF inhibitors, 
are excluded. 
 
m) A number of important costs are excluded 
- costs of institutionalisation due to disability are excluded 
- costs of longer-term surgeries unless they are represented in the first 18 
months BSRBR data 
- costs to (or quality of life impact on) carers 
- lost work productivity due to disability among patients of working age 
 
n) The probabilistic sensitivity analysis approach is valid for most of the variables 
based on BSRBR data but for some other, particularly on costs of drug and 
monitoring, we have assumed standard cost.  This may under-estimate the 
overall uncertainty somewhat.  
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6. APPENDICES 
 
6.1. APPENDIX 1 – BASIC DATA FOR VALIDATION 
 
1. Baseline HAQ  
 Baseline HAQ  Distribution of HAQ  
 n Mean HAQ  0-.5 .5 to 1 1 to 1.5 1.5 to 2 2 to 2.5 2.5 to 3 
DMARD 482 1.63 11.62 12.24 19.71 22.41 22.61 11.41 
Biologics (all) 6165 2.1 1.41 3.44 10.82 26.44 36.79 21.1 
 
2. Baseline EQ5D 
 Baseline EQ5D Distribution of EQ5D 
 n Mean EQ5D <-0.5 -0.4 -0.3 -0.2 -0.1 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 
DMARD 432 0.46 0.93 0 0.23 0 0.93 2.31 6.02 6.94 9.72 7.41 14.35 16.9 13.89 13.66 6.71 0 
Biologics (all) 5981 0.293 1.14 0.02 0.47 1.15 2.22 4.9 10.87 12.52 15.63 16.62 15.28 9.55 5.78 3.09 0.7 0.05 
 
3. Baseline SF6D 
 
 
 
 Baseline SF6D Distribution of SF6D 
 n Mean SF6D <-0.5 -0.4 -0.3 -0.2 -0.1 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 
DMARD 427 0.565 0 0 0 0 0 0 0 0 0 9.13 18.74 38.64 21.78 9.13 6.71 0 
Biologics (all) 5827 0.486 0 0 0 0 0 0 0 0 0 22.45 33.33 34.58 7.6 1.49 0.7 0.05 
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4. Mean HAQ change from baseline to 6 months 
 All patients DAS good responders DAS moderate 
responders 
Not good or moderate DAS good and mod 
combined 
 n Mean n Mean n Mean n Mean n Mean 
DMARD 30 -0.079 10 -0.425 12 -0.104 8 0.391 22 -0.25 
Biologics (all) 1681 -0.33 367 -0.533 958 -0.327 356 -0.128 1325 -0.384 
 
5. Mean EQ5D change from baseline to 6 months 
 All patients DAS good responders DAS moderate 
responders 
Not good or moderate DAS good and mod 
combined 
 n Mean n Mean n Mean n Mean n Mean 
DMARD 31 -0.001 10 0.116 12 -0.002 9 -0.128 22 0.052 
Biologics (all) 1617 0.144 352 0.192 922 0.157 343 0.062 1274 0.166 
 
6. Mean SF6D change from baseline to 6 months 
 All patients DAS good responders DAS moderate 
responders 
Not good or moderate DAS good and mod 
combined 
 n Mean n Mean n Mean n Mean n Mean 
DMARD 23 0.017 7 0.106 10 -0.016 6 -0.03 17 0.034 
Biologics (all) 1599 0.082 351 0.117 910 0.086 338 0.036 1261 0.095 
 
7a. Numbers remaining on first therapy 
Time on treatment 0 6 12 18 24 30 36 42 48 54 60 
DMARD arm *            
Biologics (all) 0 41.72 27.41 16.05 8.52 6.29 0 0 0 0 0 
* Difficult to find for DMARDS as a patient can be on up to three DMARDS at a time. 
   Only looked at non-censored patients 
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7b. Kaplan Meier survival on first therapy 
Time on treatment 0 6 12 18 24 
DMARD arm *      
Biologics (all) 1 0.952 0.839 0.779 0.722 
* Difficult to find for DMARDS as a patient can be on up to three DMARDS at a time. 
 
7c. Mean HAQ for survivors on first therapy 
Time on treatment 0 6 12 18 24 
Biologics (all) 2.099 1.763 1.701 1.725 1.654 
* Difficult to find for DMARDS as a patient can be on up to three DMARDS at a time. 
   Only look at non-censored patients 
   On therapy for at least 6 months 
 
7d. Mean EQ5D for survivors on first therapy 
Time on treatment 0 6 12 18 24 
Biologics (all) 0.293 0.446 0.456 0.454 0.47 
 
7e. Mean SF6D for survivors on first therapy 
Time on treatment 0 6 12 18 24 
Biologics (all) 0.486 0.574 0.583 0.581 0.594 
 
8a. Numbers remaining on first therapy for good and moderate responders at 6 months 
Time on treatment 0 6 12 18 24 30 36 42 48 54 60 
DMARD arm *            
Biologics (all) 0 4.3 40.46 28.57 15.6 11.06 0 0 0 0 0 
* Difficult to find for DMARDS as a patient can be on up to three DMARDS at a time. 
   Only look at non-censored patients 
 
8b. Kaplan Meier survival on first therapy for good and moderate responders at 6 
months 
Time on treatment 0 6 12 18 24 
DMARD arm *      
Biologics (all) 1 0.957 0.895 0.841 0.786 
 
8c Mean HAQ for survivors on first therapy for Good and Moderate responders at 6 
months 
Time on treatment 0 6 12 18 24 
Biologics (all) 2.088 1.688 1.664 1.684 1.664 
* Difficult to find for DMARDS as a patient can be on up to three DMARDS at a time. 
   Only look at non-censored patients 
 
8d Mean EQ5D for survivors on first therapy for Good and Moderate responders at 6 
months 
Time on treatment 0 6 12 18 24 
Biologics (all) 0.3 0.475 0.471 0.463 0.463 
 
8e Mean SF6D for survivors on first therapy for Good and Moderate responders at 6 
months 
Time on treatment 0 6 12 18 24 
Biologics (all) 0.487 0.588 0.588 0.584 0.592 
 
 
9a Numbers remaining on first therapy for poor responders at 6 months 
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Time on treatment 0 6 12 18 24 30 36 42 48 54 60 
DMARD arm *            
Biologics (all) 0 17.28 49.54 19.45 8.7 5.03 0 0 0 0 0 
* Difficult to find for DMARDS as a patient can be on up to three DMARDS at a time. 
   Only look at non-censored patients 
 
9b Kaplan Meier survival on first therapy for poor responders at 6 months 
Time on treatment 0 6 12 18 24 
DMARD arm *      
Biologics (all) 1 0.827 0.596 0.516 0.456 
* Difficult to find for DMARDS as a patient can be on up to three DMARDS at a time. 
 
9c Mean HAQ for survivors on first therapy for poor responders at 6 months 
Time on treatment 0 6 12 18 24 
Biologics (all) 2.22 2.081 1.979 1.991 1.854 
* Difficult to find for DMARDS as a patient can be on up to three DMARDS at a time. 
   Only look at non-censored patients 
 
9d Mean EQ5D for survivors on first therapy for poor responders at 6 months 
Time on treatment 0 6 12 18 24 
Biologics (all) 0.26 0.335 0.357 0.382 0.364 
 
9e Mean SF6D for survivors on first therapy for poor responders at 6 months 
Time on treatment 0 6 12 18 24 
Biologics (all) 0.474 0.514 0.542 0.552 0.537 
 
10b Kaplan Meier survival on any biologic therapy 
Time on treatment 0 6 12 18 24 
DMARD arm      
Biologics (all) 1 0.998 0.933 0.907 0.882 
 
10c Mean HAQ for survivors on any biologic therapy 
Time on treatment 0 6 12 18 24 
Biologics (all) 2.099 1.774 1.742 1.766 1.717 
   Difficult to find for DMARDS as a patient can be on up to three DMARDS at a time. 
   Only look at non-censored patients 
   On therapy for at least 6 months 
 
10d Mean EQ5D for survivors on any biologic therapy 
Time on treatment 0 6 12 18 24 
Biologics (all) 0.293 0.44 0.442 0.442 0.449 
 
10e Mean SF6D for survivors on any biologic therapy 
Time on treatment 0 6 12 18 24 
Biologics (all) 0.486 0.57 0.576 0.574 0.586 
 
 
 
 
 
11b Kaplan Meier survival on any biologic therapy for Good and Moderate responders 
at 6 months 
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Time on treatment 0 6 12 18 24 
DMARD arm      
Biologics (all) 1 0.998 0.969 0.948 0.927 
 
11c Mean HAQ for survivors on any biologic therapy for Good and Moderate 
responders at 6 months 
Time on treatment 0 6 12 18 24 
Biologics (all) 2.088 1.694 1.684 1.703 1.683 
   Difficult to find for DMARDS as a patient can be on up to three DMARDS at a time. 
   Only look at non-censored patients 
 
11d Mean EQ5D for survivors on any biologic therapy for Good and Moderate 
responders at 6 months 
Time on treatment 0 6 12 18 24 
Biologics (all) 0.3 0.473 0.461 0.461 0.459 
 
11e Mean SF6D for survivors on any biologic therapy for Good and Moderate 
responders at 6 months 
Time on treatment 0 6 12 18 24 
Biologics (all) 0.487 0.586 0.585 0.582 0.587 
 
12b Kaplan Meier survival on any biologic therapy for poor responders at 6 months 
Time on treatment 0 6 12 18 24 
DMARD arm *      
Biologics (all) 1 0.998 0.855 0.813 0.769 
* Difficult to find for DMARDS as a patient can be on up to three DMARDS at a time. 
 
12c Mean HAQ for survivors on any biologic therapy for poor responders at 6 months 
Time on treatment 0 6 12 18 24 
Biologics (all) 2.22 2.067 2.017 2.047 1.961 
   Difficult to find for DMARDS as a patient can be on up to three DMARDS at a time. 
   Only look at non-censored patients 
 
12d Mean EQ5D for survivors on any biologic therapy for poor responders at 6 months 
Time on treatment 0 6 12 18 24 
Biologics (all) 0.26 0.335 0.353 0.35 0.328 
 
12e Mean SF6D for survivors on any biologic therapy for poor responders at 6 months 
Time on treatment 0 6 12 18 24 
Biologics (all) 0.474 0.513 0.532 0.531 0.556 
 
13a Mean HAQ worsening after withdrawal 
Time on treatment 0 6 12 18 
Biologics (all) 2.148 2.128 2.092 NA 
 
13a Mean HAQ worsening after withdrawal (number) 
Time on treatment 0 6 12 18 
Biologics (all) 137 74 15 0 
13b Mean EQ5D worsening after withdrawal 
Time on treatment 0 6 12 18 
Biologics (all) 0.29 0.282 0.301 NA 
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13b Mean EQ5D worsening after withdrawal (number) 
Time on treatment 0 6 12 18 
Biologics (all) 141 76 15 0 
 
13c Mean SF6D worsening after withdrawal 
Time on treatment 0 6 12 18 
Biologics (all) 0.515 0.51 0.486 NA 
 
13c Mean SF6D worsening after withdrawal (number) 
Time on treatment 0 6 12 18 
Biologics (all) 135 69 15 0 
 
14a Mean HAQ worsening after withdrawal for moderate and good responders 
Time on treatment 0 6 12 18 
Biologics (all) 2.089 2.106 2.25 NA 
 
14a Mean HAQ worsening after withdrawal for moderate and good responders 
(number) 
Time on treatment 0 6 12 18 
Biologics (all) 52 27 4 0 
 
14b Mean EQ5D worsening after withdrawal for moderate and good responders 
Time on treatment 0 6 12 18 
Biologics (all) 0.338 0.324 0.301 NA 
 
14b Mean EQ5D worsening after withdrawal for moderate and good responders 
(number) 
Time on treatment 0 6 12 18 
Biologics (all) 53 28 4 0 
 
14c Mean SF6D worsening after withdrawal for moderate and good responders 
Time on treatment 0 6 12 18 
Biologics (all) 0.543 0.521 0.425 NA 
 
14c Mean SF6D worsening after withdrawal for moderate and good responders 
(number) 
Time on treatment 0 6 12 18 
Biologics (all) 51 27 4 0 
 
15a Mean HAQ worsening after withdrawal for poor responders 
Time on treatment 0 6 12 18 
Biologics (all) 2.182 2.188 2.125 NA 
 
 
 
15a Mean HAQ worsening after withdrawal for poor responders (number) 
Time on treatment 0 6 12 18 
Biologics (all) 59 32 6 0 
 
15b Mean EQ5D worsening after withdrawal for poor responders 
Time on treatment 0 6 12 18 
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Biologics (all) 0.272 0.257 0.334 NA 
 
15b Mean EQ5D worsening after withdrawal for poor responders (number) 
Time on treatment 0 6 12 18 
Biologics (all) 62 33 6 0 
 
15c Mean SF6D worsening after withdrawal for poor responders 
Time on treatment 0 6 12 18 
Biologics (all) 0.5 0.501 0.533 NA 
 
15c Mean SF6D worsening after withdrawal for poor responders (number) 
Time on treatment 0 6 12 18 
Biologics (all) 0.272 0.257 0.334 NA 
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6.2. APPENDIX 2 PREVIOUS RESEARCH FUNDING CONFLICTS OF 
INTEREST STATEMENT 
 
At the time of the analysis, Alan Brennan (AB) and Nick Bansback (NB) had received 
previous research funding from 3 companies for work in rheumatoid arthritis (see 
below).  This work was completed and declared prior to applying with the ARC 
Epidemiology Unit to undertake analysis of the BSRBR data.  AB and NB have also 
previously received research funding from 1 company for work on biologics in other 
indications (see below).  Again, this work was completed and declared prior to applying 
with the ARC Epidemiology Unit to undertake analysis of the BSRBR data. AB and NB 
have received sponsorship to academic conferences from 2 companies  
 
Colleagues in ScHARR are completing a separate analysis for 1 company. 
Other ongoing work does not represent a conflict of interest. 
 
AB and NB have completed the following projects in the area of biologics in RA:  
1. Modelling cost effectiveness of etanercept in the UK. Funded by Wyeth. Project 
completed 2001.  
2. Modelling cost effectiveness of adalimumab  in 10 countries including the US. 
Funded by Abbott. Project completed June 2004  
3. Cost effectiveness of a genetic test to detect responders to anakinra. funded by 
Interleukin Genetics. Completed 2002.  
 
AB and NB has also been involved in projects concerning biologics in other indications: 
4. Cost effectiveness of etanercept in the treatment for Psoriatic Arthritis. Funded 
by Wyeth. Completed  
 
AB , NB and RN have two further projects related to RA.   
5. Funded by United States Government (Agency for Healthcare Research and 
Quality) researching biologics in RA (to complete June 2005). 
6. A methodology project examining methods for optimising clinical trial 
development decisions, using RA therapies as one case study.  This is funded by 
a company, which does not have a biologic product in the RA market.  
 
Other University of Sheffield staff  
7. Cost effectiveness of etanercept in the treatment of Ankylosing spondylitis. 
Funded by Wyeth, completing 2005. (This project has not involved the staff 
working on the BSR registry analysis). 
 
Richard Nixon:- declares no conflict of interest. 
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6.3. APPENDIX 3 – EQ5D MAPPING 
 
In submission – not to be quoted, cited or distributed without the authors prior consent 
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Using the Health Assessment Questionnaire to estimate preference-based single indices in 
patients with Rheumatoid Arthritis 
 
Nick Bansback [1,3] 
Carlo Marra, [2] 
Aki Tsuchiya [3]  
Aslam Anis [1] 
Daphne Guh [1]  
Tony Hammond [4]  
John Brazier [3]  
 
Abstract 
Objective. To estimate the preference-based measures, EQ-5D and SF-6D from the Health 
Assessment Questionnaire Disability Index (HAQ-DI) in patients with Rheumatoid Arthritis 
(RA), and to characterise components that are predictors of health state utility. 
Methods. Patients participating in two studies in the UK (n=132) and Canada (n=310) with RA, 
were administered the HAQ, EQ-5D and the SF-36. The SF-36, a generic measure of quality of 
life was converted into the preference-based SF-6D. From these results we developed models of 
the relationship between the HAQ and SF-6D and EQ-5D using various regression analyses. 
Results. The optimal model developed for the EQ-5D entered levels for each item as 
independent variables. A Root Mean Squared Error(RMSE) of 0.18 suggested a relatively good 
fit. For the SF-6D, RMSE were lower (equal to 0.09) suggesting better predictions than for EQ-
5D, but models with more explanatory variables did not improve the results. For both measures, 
components of the reach dimension appeared the least predictive variables whilst the 
components of arising, eating, hygiene and activities appeared to be most important. 
Conclusions. Our approach enabled calculations of quality adjusted life years (QALYs) from 
existing trials where only the HAQ has been measured. All of the aspects of the HAQ may not 
be reflected in the preference-based measures, and this method is suboptimal to direct 
measurement of health state utility in clinical trials. Given this limitation, our approach provides 
an alternative for researchers who need health-state utility values, but had not included a 
preference-based measure in their clinical study because of resource constraints or a desire to 
limit the patient burden. 
Key Words: economics, utility theory, rheumatoid arthritis, Quality-Adjusted Life Years  
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Introduction 
Given the scarcity of health care resources, public and private agencies have become interested 
in both the effectiveness and cost-effectiveness of health care interventions.[1] The preferred 
approach towards measuring benefits in cost effectiveness analyses is to value health status in a 
single unit of measurement known as utilities which are used to derive "quality adjusted life 
years" (QALYs). Such cost utility analyses (CUA) are particularly informative for health policy 
decisions because they allow direct comparison of the efficiency of healthcare resource 
expenditure across a wide variety of conditions and treatments.[2] Utilities are obtained by 
asking patients to make judgments about the value of particular health states or outcomes. 
Preference-based instruments are formal methods for quantifying these judgments and can be 
obtained directly from patients, or from one of a number of generic measures valued by general 
population samples, such as the Health Utilities Index or EQ-5D. 
 
Many clinical studies do not use a preference-based measure due to lack of resources or time, or 
because the commonly used generic preference-based measures are regarded as unsuitable for 
the condition.[3] In a majority of Rheumatoid Arthritis (RA) clinical trials the Health 
Assessment Questionnaire is the primary and often sole measure of quality of life.[4] While the 
HAQ was primarily designed to measure only aspects of physical function and pain, it has been 
shown to be highly correlated with many generic and disease-specific measures of health related 
quality of life.[5] Subsequently, linear transformations between HAQ and utility have 
previously been used in CUA.[6,7]. While other disease specific measures such as the RAQol 
are being developed, only more recent clinical trials have measured a preference based 
measure.[8]  
 
As a result, there are many clinical trials whose results are not amenable to populating CUA. 
Estimating a relationship between the HAQ and a preference-based measure would make it 
possible to estimate QALY scores from existing clinical data where the HAQ has been 
measured but preference based instruments have not.[3,9] Moreover, in trials where one such 
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preference based instrument had been measured, it could also be possible to evaluate another. 
Such analyses have previously been attempted for outcomes in asthma and obesity.[9,10]  This 
paper uses data from the UK and Canada to map two such preference based instruments, the 
EQ-5D and the SF-6D from the HAQ questionnaire. 
 
The instruments 
Health Assessment Questionnaire 
 
The HAQ is a self-completed questionnaire, developed as a comprehensive measure of outcome 
in patients with a wide variety of rheumatic diseases, including rheumatoid arthritis, 
osteoarthritis, juvenile rheumatoid arthritis, lupus, scleroderma, ankylosing spondylitis, 
fibromyalgia, and psoriatic arthritis. Although its complete form includes an assessment of 
mortality, disability, pain and symptom levels, drug side-effects and resource utilization, most 
studies in practice only use the physical disability scale. This scale assesses upper and lower 
limb function in relation to the degree of difficulty encountered in performing daily living tasks. 
These tasks include walking, dressing, bathing and shopping. The HAQ contains 20 items 
distributed across eight components. The scores range from 0 (without any difficulty) to 3 
(unable to do). The highest score on any item within one component represents the dimension 
score. The respondent also indicates whether he or she uses aids or devices (14 items) or help 
from other people (8 items). The scores for each dimension are corrected for the use of aids or 
devices, summated and transformed to give an overall disability index (HAQ-DI) between 0-3. 
A score of 0 represents no disability and 3 very severe, high-dependency, disability.[4]  
 
EQ-5D 
 
The EQ5D has five dimensions: mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression. Each dimension has one item, and each item has three levels with 1 
denoting no problems and 3 denoting extreme problems.[11] The number of theoretically 
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possible health states is 35 = 243. EQ5D can be reported in terms of a 5-digit profile indicating 
the level on each dimension, or in terms of a preference-based single index number. The latter is 
obtained by applying algorithms that link the 5-digit health state description with average 
valuations obtained from members of the public using the time trade-off method, or the visual 
analogue scale. In this study, EQ5D indices are obtained using the so-called MVH A1 value set, 
derived from a population survey in the UK using 10-year time trade-offs.[12] 
 
SF-6D 
 
The SF-6D has been derived from the SF-36.[13] The SF-36 is a generic measure of health that 
generates scores across eight dimensions of health.[14]  It has become one of the most widely 
used generic measures of health through out the world, but was it not originally designed for use 
in economic evaluation.  A research team at the University of Sheffield in collaboration with Dr. 
Ware has estimated a preference-based single index measure of health from the SF-36.[13] The 
index is estimated via a health state classification called the SF-6D derived from the SF-36 and 
is composed of six multi-level dimensions of health.  It was constructed from a sample of 11 
items selected from the SF-36 to minimise the loss of descriptive information and defines 
18,000 health states.  A selection of 249 states defined by the SF-6D have been valued by a 
representative sample of the UK general population (n=611) using the standard gamble (SG) 
valuation technique. Like the EQ-5D, regression models were estimated to predict single index 
scores for all health states defined by the SF-6D.  The resultant algorithm can be used to convert 
SF-36 data at the individual level to a preference-based index. 
 
Table 1: Characteristics of quality of life instruments   
 
Materials and Methods  
Study populations 
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Participants from two locations were recruited. In Vancouver, Canada, 319 patients with a 
clinical diagnosis of Rheumatoid Arthritis were followed up quarterly over 3 time periods from 
eight private rheumatology offices. In Maidstone Hospital, UK, a single observation from 151 
patients with a clinical diagnosis of Rheumatoid Arthritis was measured under routine 
management in a district hospital department of Rheumatology. All patients were administered 
the HAQ, SF-36 and EQ-5D. The two samples were pooled to create a single source (total of 
925 observations) which we hoped would provide estimates more generalisable to North 
American and European populations(Table 2). The predictive ability of the estimates on the two 
individual cohorts is also studied.  
 
Table 2: Summary Statistics of the two cohorts 
 
Statistical analysis 
 
For the primary analysis, the relationships between scores on the EQ-5D, SF-6D and the HAQ-
DI were examined by fitting linear regression models estimated by generalised estimating 
equation (GEE) algorithms where the correlation matrix takes the structure of an auto regressive 
of order 1. The effect of pooling populations from two different countries was explored. The 
generalisability of the models is examined using 3-fold cross validation where the data is split 
into 3 subsets stratified by country. The following regression models were evaluated: 
 
Model 1: EQ-5D & SF-6D indices regressed on the HAQ-DI score. This assumes that the 
8 dimensions of the HAQ-DI carry equal weight; the 42 items within a given domain 
carry equal weight; and the intervals between response choices for each item are equal; 
Model 2: EQ-5D & SF-6D indices regressed on the 8 HAQ-DI dimension scores, where 
the dimension is treated as continuous variable. This assumes that the 42 items of HAQ-
DI carry equal weight within a given domain and the intervals between response choices 
for each item are equal; 
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Model 3: EQ-5D & SF-6D indices regressed on the 42 HAQ-DI item scores, where the 
responses to each item are treated as a continuous scale. This assumes that the intervals 
between response choices for each item are equal; 
Model 4: EQ-5D & SF-6D indices regressed on the individual levels of the HAQ-DI 
dimension scores, where each level is entered as a dummy variable with level one as the 
baseline (i.e., 3 x 8 dummy codes representing the 4 possible responses for each 
dimension). This assumes that the 42 items have equal weight within a given domain but 
does assume the dimensions have cardinal properties. 
Model 5: EQ-5D & SF-6D indices regressed on the individual levels of the HAQ-DI item 
scores, where each level is entered as a dummy variable with level one as the baseline 
(i.e., 3 x 20 dummy codes representing the 4 possible responses for each item of the 8 
domains, and 1 x 22 dummy codes representing the dichotomous parameters). This makes 
the least stringent assumptions and does not assume that the response choices have 
cardinal properties. 
 
The significance or sign of the beta coefficients was not of primary interest of this exercise 
given we are interested in predictive ability rather than explanatory power of the variables. 
Since most datasets will collect all items of the HAQ, all coefficients were included in the final 
models of 1 to 3. Due to the large number of dummy variables in models 4 and 5 this was not 
practical. Instead, they were developed using a backwards stepwise selection procedure, 
systematically removing the least significant variable until only significant variables remain 
(p<0.05). Residual plots were examined for nonlinear patterns and non-constant error variance. 
Final regression models were then assessed by 3-fold cross validation and applied to the UK and 
Canadian samples.  
 
The criterion for judging the performance of the model is the goodness of fit between observed 
and predicted outcomes as reported in terms of the root of the mean square error 
(RMSE).[Error! Bookmark not defined.] This is the most indicative measure given the 
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objective of the analyses is not to explain the relationship between the HAQ-DI and the EQ-5D 
and the SF-6D indices, but to predict the EQ-5D and SF-6D indices from the HAQ-DI. Any 
reduction in performance between the development and cross-validation sample RMSE is 
reported. 
 
Results 
At baseline, patients in the Canadian cohort were slightly older (61 versus 56 p<0.001) and a 
greater percentage of patients were female (78% versus 67%, p<0.01). The mean HAQ in the 
UK patients was substantially higher (1.41 versus 1.11, p<0.01). This was reflected in both the 
EQ-5D scores where UK patients had a statistically significant different mean score of 0.51 
versus 0.63 in the Canadian patients, and the SF-6D where UK patients had a mean score of 
0.62 versus 0.68 in the Canadian sample. In total, there were 16 missing HAQ-DI responses, 4 
EQ-5D, and 17 SF-6D (all less than 2% of the study population). (Table 2) 
The Canadian population had a small but significantly higher estimated utility score, above what 
was explained by HAQ-DI (B=0.06 for EQ-5D and B=0.04 for SF-6D, p<0.05). However, as no 
country effect was found on the interaction with HAQ components (i.e. the gradient), an 
estimated utility gain using these algorithms would not be changed by this difference between 
countries. We have therefore presented the mean estimates from an amalgamated data source of 
patients from both countries. Examination of plots of predicted versus actual utility for the 
models suggest a relatively linear relationship between HAQ-DI and utility(Figure 1). 
 
Table 2: Summary statistics of the two cohorts 
Figure 1: Predicted versus actual SF-6D (top) and EQ-5D (bottom) scores.  
 
In model 1, regressions resulted in a RMSE of 0.207 and 0.092 in the EQ-5D and SF-6D 
respectively.(Table 3) As expected there was a negative relationship between the HAQ-DI and 
the EQ-5D (Beta = -0.210) and the SF-6D (Beta = -0.101), which were statistically significant 
(p<0.001).(Table 4)  
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Table 3: Performance for models 1 to 5 
Table 4: Final regression equations for models 1 and 2 
 
The RMSE slightly improved when model 2 was analysed (equal to 0.202 (EQ-5D) and 0.089 
(SF-6D)) (Table 4). All coefficients were negative except for hygiene (i.e. a worsening in 
hygiene predicts an improvement in utility), but neither coefficients were statistically 
significant. Other non significant terms were the grip dimension for the EQ-5D (p=0.671) and 
the dressing and grooming dimension for the SF-6D (p=0.093). 
Again, in model 3, the RMSE improved in the development sample as compared to the previous 
model (RMSE = 0.189 and 0.086 in the development set EQ-5D and SF-6D respectively). 
However the cross validation demonstrated that the RMSE could be as high as 0.206 and 0.095 
for the EQ-5D and SF-6D respectively, figures that are greater than the RMSE seen in the cross 
validation of model 1. On their own, getting in and out of bed (H4), using crutches (H12), help 
from another person with walking (H21), bending down to pick something off the floor (H26) 
and doing chores such as vacuuming or yardwork (H32) were the only statistically significant 
variables in the EQ-5D prediction. In the SF-6D prediction, shampooing your hair (H2) getting 
in and out of bed (H4), washing and drying your body (H22), opening jars (H28), doing chores 
such as vacuuming or yardwork (H32), other aids or devices (H38), and help in errands and 
chores from another person (H42) were statistically significant variables. (Table 5) 
 
Table 5: Final regression equations for model 3 
 
In model 4, the RMSE worsened from model 3 (to 0.199 and 0.088). Cross validation 
demonstrated again that the model 4 performed no better than models 1 and 2. Some 11 of the 
24 variables were included in the EQ-5D, while 13 of the 24 variables were included in the SF-
6D.(Table 6) Elements of dressing and grooming did not feature in either the EQ-5D and SF-6D 
estimates. Six components were predictors of both the EQ-5D and the SF-6D.  
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Table 6: Final regression equations for model 4 
 
Lastly, model 5 gave the best performance for the EQ-5D with a RMSE’s of 0.183 and 0.178 in 
the developmental and cross validation set respectively. The results for the SF-6D were no 
better than model 3 with RMSE’s of 0.086 and 0.087. In the SF-6D, no components of the reach 
dimension were included in the final model.  More items in the components of arising, eating, 
hygiene and activities were included than in the other components.(Table 7)  
 
Table 7: Final regression equations for model 5 
 
Discussion 
 
We anticipated that models with more available predictors would account for a higher 
proportion of the variance and would therefore perform better as measured by the RMSE. While 
this hypothesis was accurate for the EQ-5D where model 5 proved to be the best performing, it 
was not the case for the SF-6D or models 2 to 4 for the EQ-5D. The results for the cross 
validation are perhaps the most important as they predict how generalisable the models will be 
to external populations. This would indicate that model 5 is the most appropriate model for 
estimating the EQ-5D, whilst model 2 or model 4 the most appropriate for the SF-6D. The 
performance of models for the SF-6D always outperformed models for the EQ-5D due to the 
smaller range in scale of the SF-6D. While the benefits of using the later models versus the 
simple estimate in model 1 would seem small in terms of the change in RMSE’s, these models 
on the whole will provide more accurate estimates, partly due to their ability to account for the 
small non linearity seen in the relationship between HAQ and utility, particularly at severe 
states of disability. (Figure 2)  
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There are a number of important issues that need further consideration. Firstly, whether these 
results would be generalisable to external populations. To address this we developed the models 
using a combination of data from the UK and Canada. Patients in the Canadian dataset were 
older but had less severe RA. The mean HAQ-DI for both patient groups is similar to many 
studies recently published analysing the effectiveness of biologic therapies. Comparisons 
between Canadian and UK RA patients’ quality of life have previously been explored and the 
differences between the two cohorts is not be unexpected.[15] This heterogeneity is important as 
it means the models can be used for estimation across a wider range of patients. The country 
effect discovered would appear not to be due to age since the Canadian population was older, 
but could have been due to another clinical or demographic characteristic not measured in our 
study. The models were tested on both the UK and Canadian samples. RMSE were always 
higher for the UK population since there was a smaller sample in which to test. Further external 
validation would always add assurance to the results, but we consider the results as they stand as 
good predictions. 
Secondly, this exercise provides a method that will always be suboptimal in comparison to a 
trial that uses a preference-based questionnaire directly. Given the objectives of the study, there 
are other approaches that could be employed to derive a single index from the HAQ-DI. A 
survey of the general population could be used to value a sample of states defined by the HAQ-
DI using a preference elicitation technique such as standard gamble (SG) or time trade-off 
(TTO). This would not only generate an enormous number of health states but more importantly 
each state would contain 42 pieces of information, which most respondents would find 
impossible to process. Instead, a selection of the most important items of the HAQ-DI could be 
selected, similar to how the SF-6D uses only 15 questions from the SF-36. Another approach is 
to administer the HAQ alongside a preference-elicitation technique such as TTO and SG. 
Regression techniques could then estimate preference weights for each of the items of the HAQ-
DI using the SG or TTO response as the dependent variable. However, results from such a study 
would not meet the reference case for either NICE or the Washington Panel on Cost 
Effectiveness in Medicine who prefer social preferences elicited using a choice-based 
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method.[16,2] This exercise could act as a precursor to such studies, but given limited resources, 
we have undertaken a more pragmatic approach. 
Lastly, there has been an argument that the HAQ-DI does not adequately measure aspects of 
quality of life, measured by the preference based instruments such as mental health and 
pain.[17] Given this, the models show that HAQ-DI does explain much of the preference based 
measures we have studied, with small RMSE’s (<0.2). Perhaps such aspects of quality of life 
such as pain are highly correlated to domains so are indirectly covered. Explaining why there is 
a relationship between the two measures was not the purpose of this study, but rather exploring 
if there is a translation between the two measures. Importantly, the method described in this 
paper is not designed and would not predict accurately the utility of an individual but rather 
predict the average utility of a cohort. Figure 2 demonstrates that across the range of the HAQ-
DI, the model prediction for both the EQ-5D and SF-6D is close. Only in the first group (HAQ 
0 - .5) is the prediction significantly different to the actual utility (p= <0.01). Even in the higher 
HAQ groups where we have less patients, the predictions appear good.  
 
Figure 2: Predicted and Actual EQ-5D scores and confidence intervals across HAQ groups 
within the sample 
 
Another argument concerns whether the generic utility based measures are accurate 
representations of patients’ preferences in RA. Aspects of the condition captured by the HAQ-
DI might not be covered in the preference-based measures. Concerns about the EQ-5D and SF-
6D in RA patients have previously been demonstrated.[18] This paper is not aimed to make 
claims on the superiority or defects of different preference-based measures, but to give 
researchers a method of estimating these what are now frequently used instruments.  
Much of the paper has concentrated on studies where no preference-based measure has been 
administered. Given the SF-6D does not perform well in patients with severe RA due to a floor 
effect, there is potentially a use when only one preference-based questionnaire is 
administered.[18,19] This is the case in the British Society for Rheumatology Biologics 
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Registry (BSRBR) that measured only the SF-36 
(http://www.arc.man.ac.uk/webbiologicsreg.htm). This approach would allow an estimate of 
EQ-5D utility to additionally be calculated.  
The approach examined in this article is to empirically map the relationship between a non-
preference-based HRQOL instrument and a preference-based measure. The approach has the 
advantage of being able to utilise existing valuation data and offers a shortcut for researchers 
who need health-state utility values, but have not used a preference-based measure in their 
clinical study because of resource constraints or a desire to limit the patient burden. This could 
be used to estimate the improvement in utility in important trials such as the ATTRACT trial of 
infliximab or the TEMPO etanercept trial.[20,21] The results presented here suggest that such a 
model can be useful in predicting preference-based values and that the models achieve a 
reasonable goodness of fit.  
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Table 1: Characteristics of quality of life instruments   
 
 Domains/ Categories Design Number of 
individual health 
state valuations 
Method of 
Scoring 
Sample Country Boundaries 
HAQ Dressing and grooming, arising, 
eating, walking, hygiene, reach, 
grip, activities 
20 questions 4 
levels each 
+ 22, 2 level 
questions 
24 Scalar NA NA 0.00-3.00 
SF-6D Physical function, role limitation, 
social function, pain, mental 
health, vitality 
6 questions 
between 4 and 6 
levels. 
18,000 Preference 
weighted 
611 
(representative) 
UK 0.30-1.00 
EQ-5D Mobility, usual activities, self-
care, pain, anxiety 
5 questions 3 
levels. 
243 Preference 
weighted 
3395 
(representative) 
UK -0.59-1.00 
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Table 2: Summary statistics of baseline characteristics in the two cohorts 
 
 UK (n=132) Canada (n=310) Total (n=442) 
 Mean  Range Mean  Range Mean  Range P† 
Sex (% Female) 67    78    76    0.009 
Mean age (SD) 56.01 (13.62)  (17-82) 61.43 (13.6)  (19-90) 60.76 (13.6)  (17-90) <0.001 
                  
HAQ Disability            
N 132   308   440    
Mean Index (SD) 1.41 (0.8)  (0-3) 1.11 (0.77)  (0-3) 1.15 (0.78)  (0-3) 0.004 
HAQ Domains, modal level (% of total)           
  Dressing & Grooming 2 (35)  (0-3) 0 (46)  (0-3) 0 (39)  (0-3) <0.001 
  Rising  1 (41)  (0-3) 0 (54)  (0-3) 0 (44)  (0-3) <0.001 
  Eating 1 (35)  (0-3) 0 (40)  (0-3) 0 (35)  (0-3) 0.001 
  Walking 2 (41)  (0-3) 0 (45)  (0-3) 0 (41)  (0-3) 0.022 
  Hygiene 2 (43)  (0-3) 3 (30)  (0-3) 0 (31)  (0-3) <0.001 
  Reach 3 (30)  (0-3) 0 (31)  (0-3) 2 (30)  (0-3) 0.001 
  Grip 2 (57)  (0-3) 2 (61)  (0-3) 2 (59)  (0-3) 0.006 
  Activities 2 (35)  (0-3) 2 (28)  (0-3) 2 (30)  (0-3) 0.469 
                  
SF-6D           
N 129   302   431    
Mean Index (SD 0.62 (0.11)  (0.27-0.92) 0.68 (0.13)  (0.26-1) 0.68 (0.13)  (0.26-1) <0.001 
SF-6D Domains, modal level (% of total)           
  Physical functioning 4 (31)  (1-6) 5 (30)  (1-6) 5 (28)  (1-6) 0.003 
  Role limitation 4 (46)  (1-4) 2 (63)  (1-4) 2 (54)  (1-4) <0.001 
  Social functioning 3 (36)  (1-5) 3 (43)  (1-5) 3 (40)  (1-5) <0.001 
  Pain 5 (33)  (1-6) 4 (27)  (1-6) 4 (27)  (1-6) 0.001 
  Mental health 3 (36)  (1-5) 2 (41)  (1-5) 2 (38)  (1-5) 0.010 
  Energy and vitality 5 (34)  (1-5) 3 (35)  (1-5) 3 (33)  (1-5) <0.001 
           
EQ-5D           
N 131   308   439    
Mean Index (SD) 0.51 (0.31)  (-0.35-1) 0.63 (0.25)  (-0.48-1) 0.62 (0.27)  (-0.48-1) <0.001 
EQ-5D Domains, modal level (% of total)           
  Mobility 2 (78)  (1-2) 2 (62)  (1-3) 2 (66)  (1-3) 0.004 
  Self Care 1 (52)  (1-3) 1 (71)  (1-3) 1 (65)  (1-3) <0.001 
  Usual Activities 2 (71)  (1-3) 2 (66)  (1-3) 2 (63)  (1-3) 0.003 
  Pain 2 (77)  (1-3) 2 (79)  (1-3) 2 (79)  (1-3) 0.008 
  Anxiety 1 (52)  (1-3) 1 (64)  (1-3) 1 (60)  (1-3) 0.001 
 
† ordinal data compared using independent sample t-tests, categorical data compared using chi-squared test 
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Table 3: Performance for models 1 to 5 
 
EQ-5D Index SF-6D Index 
Model 
RMSE 
Develop 
RMSE Cross 
Validation 
RMSE 
Canada 
RMSE 
UK 
RMSE 
Develop 
RMSE Cross 
Validation 
RMSE 
Canada 
RMSE 
UK 
1 0.2070 0.1896 0.1763 0.2558 0.0916 0.0870 0.0849 0.0986 
2 0.2021 0.1920 0.1771 0.2649 0.0886 0.0845 0.0819 0.0989 
3 0.1885 0.2056 0.1865 0.2772 0.0858 0.0955 0.0938 0.1032 
4 0.1991 0.1946 0.1776 0.2758 0.0884 0.0841 0.0814 0.0993 
5 0.1829 0.1780 0.1610 0.2410 0.0863 0.0866 0.0839 0.0983 
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Table 4: Final regression equations for models 1 and 2 
 
 
EQ-5D Index SF-6D Index Model  
B SE Z P B SE Z P 
1 HAQ index -0.2102 0.0116 -18.07 <0.001 -0.1008 0.0072 -13.96 <0.001 
 Constant 0.8553 0.0120 71.15 <0.001 0.7893 0.0087 90.36 <0.001 
2 Dressing & 
Grooming 
-0.0300 0.0111 -2.70 0.007 -0.0078 0.0046 -1.68 0.093 
 Arising -0.0522 0.0129 -4.05 <0.001 -0.0262 0.0046 -5.69 <0.001 
 Eating -0.0461 0.0113 -4.07 <0.001 -0.0178 0.0045 -3.93 <0.001 
 Walking -0.0282 0.0098 -2.89 0.004 -0.0115 0.0038 -3.08 0.002 
 Hygiene 0.0100 0.0074 1.34 0.179 0.0056 0.0031 1.82 0.069 
 Reach -0.0199 0.0082 -2.42 0.016 -0.0100 0.0037 -2.67 0.008 
 Grip -0.0035 0.0082 -0.43 0.671 -0.0142 0.0039 -3.68 0.002 
 Activities -0.0487 0.0097 -5.01 <0.001 -0.0238 0.0043 -5.55 <0.001 
 Constant 0.8371 0.0118 70.83 <0.001 0.7858 0.0091 86.00 <0.001 
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Table 5: Final regression equations for model 3 
EQ-5D Index SF-6D Index  
B SE Z P B SE Z P 
DRESSING & GROOMING          
-Dress yourself, including tying shoelaces and doing buttons? H1 0.0112 0.0192 0.59 0.558 0.0125 0.0081 1.54 0.124 
-Shampoo your hair? H2 -0.0295 0.0167 -1.77 0.077 -0.0192 0.0077 -2.52 0.012 
ARISING                  
-Stand up from a straight chair? H3 0.0049 0.0180 0.27 0.786 -0.0102 0.0081 -1.26 0.208 
-Get in and out of bed? H4 -0.0738 0.0221 -3.34 0.001 -0.0298 0.0083 -3.57 <0.001 
EATING                  
-Cut your meat? H5 0.0054 0.0169 0.32 0.751 -0.0037 0.0086 -0.43 0.666 
-Lift a full cup or glass to your mouth? H6 -0.0247 0.0176 -1.40 0.161 -0.0097 0.0085 -1.14 0.253 
-Open a new milk carton? H7 -0.0188 0.0155 -1.21 0.227 -0.0088 0.0076 -1.17 0.243 
WALKING                  
-Walk outdoors on flat ground? H8 -0.0288 0.0228 -1.26 0.207 0.0008 0.0096 0.08 0.937 
-Climb up five steps? H9 0.0166 0.0197 0.84 0.399 -0.0025 0.0075 -0.34 0.736 
AIDS OR DEVICES                  
-Cane H10 -0.0022 0.0239 -0.09 0.927 0.0032 0.0114 0.28 0.779 
-Walker H11 0.0345 0.0355 0.97 0.332 -0.0297 0.0185 -1.60 0.109 
-Crutches H12 -0.2028 0.0768 -2.64 0.008 0.0130 0.0362 0.36 0.719 
-Wheelchair H13 -0.0571 0.0527 -1.08 0.280 0.0084 0.0269 0.31 0.754 
-Dressing H14 0.0230 0.0266 0.87 0.387 0.0136 0.0112 1.21 0.225 
-Utensils H15 -0.0544 0.0328 -1.66 0.098 0.0049 0.0123 0.40 0.693 
-Chair H16 0.0518 0.0286 1.81 0.070 0.0011 0.0113 0.09 0.925 
-Other? H17 -0.0510 0.0475 -1.07 0.283 0.0072 0.014 0.51 0.607 
HELP FROM ANOTHER PERSON                  
-Dressing and grooming H18 -0.0379 0.0291 -1.30 0.193 -0.0065 0.0105 -0.62 0.536 
-Arising H19 -0.0202 0.0323 -0.62 0.533 -0.0091 0.0107 -0.85 0.396 
-Eating H20 0.0580 0.0322 1.80 0.072 -0.0142 0.0135 -1.05 0.292 
-Walking H21 0.0453 0.0204 2.22 0.027 -0.0021 0.0098 -0.22 0.828 
HYGIENE                  
-Wash and dry your body? H22 -0.0131 0.0150 -0.87 0.382 -0.0228 0.0052 -4.41 <0.001 
-Take a tub bath? H23 0.0027 0.0079 0.34 0.733 0.0017 0.0039 0.42 0.673 
-Get on and off the toilet? H24 -0.0047 0.0178 -0.26 0.791 0.0067 0.0066 1.01 0.311 
REACH                  
-Reach and get down a 5-pound object from just above your head? H25 -0.0224 0.0118 -1.90 0.058 -0.0074 0.0049 -1.52 0.129 
-Bend down to pick up clothing from the floor? H26 -0.0343 0.0160 -2.14 0.033 -0.0044 0.0064 -0.69 0.491 
GRIP                  
-Open car doors? H27 -0.0208 0.0168 -1.24 0.217 0.0092 0.0077 1.20 0.231 
-Open jars, which have been previously opened? H28 -0.0186 0.0150 -1.24 0.216 -0.0129 0.0064 -2.01 0.044 
-Turn faucets on and off? H29 -0.0227 0.0179 -1.27 0.203 -0.0028 0.0063 -0.45 0.653 
ACTIVITIES                  
-Run errands and shop? H30 -0.0167 0.0165 -1.02 0.309 -0.0022 0.0066 -0.33 0.739 
-Get in and out of a car? H31 -0.0287 0.0181 -1.59 0.112 -0.0051 0.0062 -0.82 0.412 
-Do chores such as vacuuming or yardwork? H32 -0.0345 0.0112 -3.07 0.002 -0.0157 0.0048 -3.29 0.001 
AIDS OR DEVICES                  
-Raised toilet seat  H33 -0.0316 0.0256 -1.23 0.218 0.0019 0.0112 0.17 0.862 
-Bathtub seat H34 -0.0175 0.0277 -0.63 0.528 -0.0157 0.0118 -1.33 0.184 
-Jar opener H35 0.0163 0.0185 0.88 0.378 -0.0092 0.0068 -1.35 0.179 
-Bathtub bar H36 0.0137 0.0207 0.66 0.510 0.0104 0.0086 1.21 0.226 
-Long handles appliances for reach H37 0.0126 0.0245 0.52 0.606 -0.0003 0.0105 -0.03 0.977 
-Other H38 0.0331 0.0322 1.03 0.303 -0.0278 0.0135 -2.06 0.040 
HELP FROM ANOTHER PERSON                  
-Hygiene H39 0.0420 0.0217 1.94 0.053 0.0131 0.0081 1.63 0.103 
-Reach H40 0.0052 0.0211 0.25 0.806 0.0164 0.008 2.04 0.042 
-Gripping and opening  H41 0.0363 0.0211 1.72 0.085 -0.0124 0.0081 -1.54 0.124 
-Errands and chores H42 -0.0401 0.0224 -1.79 0.074 -0.0210 0.0085 -2.48 0.013 
Constant  0.8041 0.0122 65.68 <0.001 0.7648 0.0086 89.4 <0.001 
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Table 6: Final regression equations for model 4 
 EQ-5D Index SF-6D Index  
B SE Z P B SE Z P 
Arising = 2 -0.0545 0.0189 -2.89 0.004         
Arising = 3 -0.1164 0.0531 -2.19 0.028         
Eating = 1 -0.0726 0.0189 -3.85 <0.001 -0.0247 0.0063 -3.95 <0.001 
Eating = 2 -0.085 0.0255 -3.33 <0.001 -0.0521 0.0092 -5.64 <0.001 
Eating = 3         -0.1144 0.0353 -3.24 0.001 
Walking = 1 -0.0585 0.0154 -3.80 <0.001 -0.0212 0.007 -3.02 0.002 
Walking = 2 -0.0919 0.0236 -3.90 <0.001 -0.0377 0.0102 -3.68 <0.001 
Walking = 3 -0.1888 0.0382 -4.94 <0.001 -0.0558 0.0155 -3.61 <0.001 
Hygiene = 1 -0.0578 0.0213 -2.72 0.007         
Hygiene = 3 -0.0693 0.0193 -3.59 <0.001 -0.0194 0.0066 -2.95 0.003 
Reach = 1         -0.0703 0.024 -2.93 0.003 
Reach = 2         -0.0151 0.0067 -2.24 0.025 
Reach = 3 0.0501 0.0213 2.35 0.019         
Grip = 2         -0.0199 0.008 -2.48 0.013 
Grip = 3         -0.0202 0.0086 -2.35 0.019 
Activities = 1         -0.0402 0.0122 -3.29 0.001 
Activities = 2         -0.0203 0.0061 -3.33 <0.001 
Activities = 3 -0.1418 0.0527 -2.69 0.007         
Constant -0.0606 0.017 -3.56 <0.001 -0.0331 0.0088 -3.77 <0.001 
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Table 7: Final regression equations for model 5 
EQ-5D Index SF-6D Index   
  B SE Z P B SE Z P 
DRESSING & GROOMING           
H1=2 -0.1514 0.0394 -3.85 <0.001 . . . . 
H1=3 . . . . 0.0458 0.0202 2.26 0.024 
H2=3 . . . . -0.0551 0.0166 -3.32 <0.001 
ARISING              
H4=1 -0.0762 0.0171 -4.47 <0.001 -0.0382 0.0077 -4.93 <0.001 
H4=2 -0.1150 0.0480 -2.40 0.017 -0.0881 0.0167 -5.27 <0.001 
H4=3 -0.5847 0.0813 -7.19 <0.001 -0.3443 0.0341 -10.08 <0.001 
EATING                 
H5=2 . . . . -0.0520 0.0147 -3.53 0.004 
H6=2 -0.1371 0.048 -2.86 0.004 . . . . 
H7=1 -0.0410 0.0168 -2.44 0.015 . . . . 
H7=2 -0.0783 0.0272 -2.88 0.004 . . . . 
WALKING                 
H8=2 -0.0955 0.0427 -2.24 0.025 . . . . 
H9=2 . . . . -0.0358 0.0180 -1.99 0.046 
H9=3 0.1176 0.0499 2.36 0.018 . . . . 
AIDS OR DEVICES             
H11=1 . . . . -0.0443 0.0190 -2.33 0.020 
H13=2 -0.1367 0.0411 -3.33 <0.001 . . . . 
H16=1 0.0664 0.0255 2.61 0.009 . . . . 
HELP FROM ANOTHER PERSON            
H21=1 . . . . 0.0181 0.0087 2.09 0.037 
HYGIENE                 
H22=1 . . . . -0.0284 0.0076 -3.73 0.002 
H22=2 . . . . -0.0579 0.0192 -3.02 0.003 
H22=3 . . . . -0.0507 0.0164 -3.09 0.002 
H23=1 -0.0487 0.0163 -2.99 0.003 -0.0337 0.0072 -4.66 <0.001 
H24=1 -0.0520 0.0204 -2.54 0.011 . . . . 
H24=2 -0.1131 0.0431 -2.62 0.009 . . . . 
REACH                 
H26=2 -0.1375 0.0374 -3.68 0.002 . . . . 
H26=3 -0.1344 0.0625 -2.15 0.032 . . . . 
GRIP                 
H27=2 -0.0756 0.0373 -2.02 0.043 . . . . 
H27=3 -0.2002 0.0706 -2.84 0.005 0.0540 0.0202 2.67 0.008 
H28=3 . . . . -0.0823 0.0135 -6.08 <0.001 
ACTIVITIES                 
H30=1 -0.0505 0.0189 -2.67 0.008 . . . . 
H31=1 -0.0684 0.0194 -3.52 <0.001 . . . . 
H31=2 -0.0819 0.0376 -2.18 0.030 . . . . 
H32=1 . . . . -0.0378 0.0107 -3.55 <0.001 
H32=2 . . . . -0.0613 0.0120 -5.13 <0.001 
H32=3 -0.0903 0.0276 -3.27 0.001 -0.0841 0.0176 -4.76 <0.001 
AIDS OR DEVICES             
H35=1 . . . . -0.0141 0.0066 -2.15 0.032 
H36=1 . . . . 0.0166 0.0072 2.31 0.021 
HELP FROM ANOTHER PERSON           
H41=1 . . . . -0.0157 0.007 -2.26 0.024 
Constant 0.8016 0.0107 74.67 <0.001 0.7709 0.0098 78.44 <0.001 
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Figure 1: Predicted versus actual SF-6D (top) and EQ-5D (bottom) scores.  
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Figure 2: Predicted and Actual EQ-5D (model 5) and SF-6D (model 4) scores and 
confidence intervals across HAQ groups within the sample  
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